Skip to main content
PLOS One logoLink to PLOS One
. 2021 Aug 19;16(8):e0256336. doi: 10.1371/journal.pone.0256336

Has resistance to chlorhexidine increased among clinically-relevant bacteria? A systematic review of time course and subpopulation data

Stephen Buxser 1,*
Editor: Amal Al-Bakri2
PMCID: PMC8376095  PMID: 34411140

Abstract

Chlorhexidine (CHX) was introduced for use as an antimicrobial more than 70 years ago. CHX has been and continues to be used broadly for disinfecting surfaces in medical and food service facilities as well as directly on skin of humans and animals. Considering its widespread use over many decades, questions of resistance to CHX have been raised. Additionally, questions of possible coincident resistance to the biocide and resistance to clinically relevant antibiotics have also been raised. A number of important questions remain, including is there consistent evidence of resistance, what is the degree of resistance, especially among clinically isolated microbial strains, and what is the degree of resistance compared to the typical concentrations of the biocide used? Data for microbial species isolated over the last 70+ years were compiled to construct as complete a picture as practical regarding possible resistance, especially among species in which resistance to commonly used antibiotics has been noted to be increasing. This is a compilation and analysis of individual MIC values for CHX reported in the literature, not a compilation of the conclusions individual authors reached. The data were analyzed using straight-forward and robust statistical procedures to detect changes in susceptibility to CHX over time, i.e. linear regression. Linear regression was supplemented with the use of nonlinear least squares regression analysis to detect the presence of population parameters associated with subpopulations of microbial strains which exhibit increased resistance to CHX. Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii were all found to have an increased resistance to CHX over time with the most profound change detected in A. baumannii. Additionally, subpopulations with log-normal distributions were found consistent with the presence of a baseline subpopulation of susceptible strains and a subpopulation with increased resistance to CHX. However, the CHX-resistant subpopulations did not correlate exactly with antibiotic resistance, so details of the relationship remain to be addressed. Increased resistance over time was not detected for Escherichia coli, Enterobacter faecalis, Staphylococcus aureus, or Candida albicans, although a subpopulation with greater than baseline resistance to CHX was detected among strains of E. faecalis and C. albicans. A difference in susceptibility to CHX was also detected between methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) S. aureus strains. The levels of resistance to CHX detected were all markedly lower than concentrations routinely used in medical and food service applications. Reaching conclusions regarding the relationship between antibiotic and CHX resistance was complicated by the limited overlap between tests of CHX and antibiotic resistance for several species. The results compiled here may serve as a foundation for monitoring changes in resistance to CHX and possible relationships between the use of CHX and resistance to antibiotics commonly used in clinical medicine.

Introduction

The antimicrobial properties of chlorhexidine (CHX) were described in 1954 [1]. Since then the compound has been used as a topical antiseptic incorporated into many commercial products, especially since the 1970s. For a list of products and marketing dates see https://go.drugbank.com/drugs/DB00878. Further history of CHX use is found in https://www.chlorhexidinefacts.com/history-of-chlorhexidine.html. CHX is commonly used orally in dentistry for treatment of inflammatory dental conditions as well as for skin disinfection before surgery, for sterilization of surgical instruments, and as a cleaning and disinfecting agent for surfaces in food preparation and medical facilities. CHX is a broad spectrum disinfectant with activity against Gram-positive and Gram-negative bacteria, fungi and viruses [2]. Recently, CHX has been considered in the context of resistance to antimicrobial agents [3, 4]. Although CHX is not an antibiotic used in clinical medicine, the possibility has been raised that the use of CHX can result in resistance to itself and to conventional antibiotics used in human and animal medicine. Shared resistance mechanisms may include decreased permeability and increased efflux transporter activity, which may be consistent with biocide resistance imparting antibiotic resistance [5]. Although it has been demonstrated that biocide resistance can be induced in many infectious bacteria and that some antibiotic resistant bacteria also have been reported to be resistant to one or more biocides, a direct causal relationship between appearance of biocide resistance and antibiotic resistance has not been definitively demonstrated. How much resistance to biocides is present in bacteria isolated from either the environment or in clinical settings has not been extensively explored. The work described below is an attempt to address the fundamental question, is there strong evidence of increasing resistance to biocides, in particular resistance to CHX, among important infectious bacteria and fungi?

The focus is purposely narrow. The approach was to compile data reporting CHX antimicrobial activity from peer-reviewed literature for microbial strains isolated over as long a period of time and covering as many important infectious organisms as there is sufficient published information to draw inferences or conclusions. The time course of measurements for CHX susceptibility and resistance varies from species to species but is at least 20 years, and data for strains isolated over more than 50 years have been included in this report. Since resistance to antibiotics varies among microbial species, an important question is whether species-to-species differences in resistance to CHX has occurred. Additionally, within a species exhibiting CHX resistance, does resistance appear as a small increase in resistance among many strains or as a high degree of resistance among a few strains? Considering the broad use of CHX, the absence of CHX resistance for some species is as important to document as is the presence and degree of CHX resistance in other species. Such differences are important to consider so that CHX resistance among resistant bacterial species may be monitored more aggressively than others.

The methodology was to compile and analyze antimicrobial values for individual strains and not to compile conclusions, statistics or summaries from previous studies. Thus, the review is accurately described as a systematic review but, because the goal was to compile raw data, the analysis is not meta-analysis. The information compiled for important bacterial infections provides insight into changes in susceptibility or resistance to CHX since the compound was introduced. The goal of this report is to provide an understanding of the degree to which CHX resistance has occurred over time in bacteria and fungi with emphasis on species with direct clinical relevance, including examining the relationship between general antimicrobial activity of CHX and whether this may affect resistance to clinically relevant antibiotics.

Methods

In microbiology, the most typical scheme for evaluating antimicrobial potency is the use of two-fold serial dilutions. In the descriptions that follow, it is conceptually and statistically useful to use the term log2(MIC) which, as the term indicates, is the base two logarithm of the MIC value. The use of this form of MIC simplifies expression of MICs to a series of integers that are easily translated back to the usual MIC concentration where, for example, 4, 2, 1, and 0.5 μg/ml is converted to values of 2, 1, 0, and -1 in log2(MIC) units.

It is also important to distinguish the use of the words “mean” and “standard deviation” into their context sensitive meanings. When referring to a series of observations, mean and standard deviation refer to summary statistics of that restricted set of values, but in the context of populations in the descriptions below, mean and standard deviation refer to population parameters summarizing the properties of log-normal distributions.

Protocol and registration

No review protocol exists for this report.

Eligibility criteria

The sole criterion for eligibility for inclusion in the compiled data was a numerical value for minimum inhibitory concentration using chlorhexidine as an antimicrobial in an in vitro assay. Predominantly, the chlorhexidine form was chlorhexidine gluconate, although a few studies used the chlorhexidine diacetate form. If CHX was included in a formulation with alcohol, detergent, or any other known co-inhibitory molecule of microbial growth, the results were excluded to prevent interference by a synergistic effect. Most reports included results from testing of strains from medical facilities, especially hospitals, although initial findings included stains isolated from non-clinical settings. When included in final results, stains from non-clinical origins are specified as such. Otherwise, results included were from clinical samples from humans. Some studies specified anatomic locations of strains reported, but results were combined from all strains regardless of anatomic source.

Information sources

Literature citations were accumulated over a period of 9 years beginning with a search of PubMed, Science Direct, and Cochrane Library databases in 2012 covering publications from as early as the 1970s up to the search date. Additional searches were carried out in March 2018 emphasizing publications appearing between 2012 and 2018 as found in Scopus, Biological Abstracts, International Pharmaceutical Abstracts, the Life Sciences Collection, and Medline. A final search for additional publications appearing between 2018 and August 13, 2020 was carried out in Science Direct and Dimensions (https://www.dimensions.ai/#). The PRISA flow diagram (Fig 1) summarizes the results and selections made for inclusion. Dates applied for MIC results from reference strains, predominantly ATCC strains, were the isolation dates stated in the source strain collection. Many reference strains were isolated in the 1940s providing the earliest isolation dates for strains compiled for this study.

Fig 1. Literature selection process.

Fig 1

Search

The search algorithm used for all searches was:

(chlorhexidine OR CHX) AND (resistance OR MIC OR “minimum inhibitory”)

Cross-checking citation lists within publications found, including review articles, was used to extend finding relevant citations.

Study selection

Other than checking for citations absent from other search results, review articles were excluded from consideration. Only reports that mentioned CHX and MICs in abstracts or titles were included for detailed consideration. Only results clearly stated as MIC values based on dilutions, i.e. not including disc diffusion results, were compiled for use in detailed statistical analyses. Initially, results from any bacterial or fungal species were considered, but final analyses were completed only for the species with results analyzed below wherein a minimum of 10 independent studies were assessed for any species with isolation dates extending at least over a 20 year interval with typical results extending over 50 or more years of strain isolation dates.

Data collection process & data items

Citations were selected for further review, if the titles or abstracts suggested that individual strains had been assessed for susceptibility to CHX using MICs. If so, full-text articles were obtained and screened for the presence of MIC values reported using in vitro serial dilutions. Most results were presented as MICs for individual strains, although many papers compiled information for more than one microbial species. Data were also included for values presented by authors as MIC50 and/or MIC90 values, if the number of strains with particular MIC values or the number of strains with MIC values within a narrow range of values could be determined. When necessary, randomization within a narrow range of possible MIC values was used to assign specific values to individual strains. Permutation runs were used to calculate the range of fitted parameters resulting from the randomizations. See S1 Appendix for details. Additionally, a date or date range for isolation of particular strains was required for inclusion. Typically, date ranges were over a two-year or shorter period. As detailed in S1 Appendix, randomization of dates was carried out within the range of isolation dates stated by authors to observe effects of isolation date uncertainties on statistical parameters calculated to detect presence or absence of changes in CHX susceptibility over time.

Randomizations of possible MIC values and isolation dates were used to assign specific values to all strains used in analyses. To account for uncertainty in MICs or isolation dates, a series of randomizations were carried out–termed “permutation runs”–to generate a series of data sets for each species. Time course datasets contained randomizations of both isolation dates and MIC values within the confines of the uncertainty in individual values. Parameters from the collection of permutation run datasets were used to assess the effect of uncertainty in the data on the time course parameters, especially on the slope of linear regression of MICs over time. At least 50 permutation runs were compiled for time-course evaluations for each species reported. Statistics of the fits of linear regression were tested using the F-test for linear regression, i.e. a test of whether the slope coefficient is different than zero. Linear regression parameters from the pooled permutation runs also included calculation of the standard error of the slope and the coefficient of determination (r2), which are also useful for assessing the precision of linear regression parameters. p-values for F-tests and for r2 values were compiled to observe variability among permutation runs. Linear regression analysis was run using Excel 2013 programs (LINEST).

Non-linear least squares regression was used to determine population and subpopulation parameters for the collection of strains from a single microbial species reported in the compiled MIC data regardless of date. Compiled MIC values for single microbial species–independent of collection date–were analyzed for conformance to a single or to the sum of two log-normal distributions. The presence of a single population indicated that no subpopulation of resistant strains was detected. Improved fit of a model for the sum of two log-normal distributions indicated the presence of a subpopulation with a base-line susceptibility to CHX and a second subpopulation with lower susceptibility/higher resistance to CHX. A parameter indicating the number of strains with lower susceptibility in the model with the sum of two log-normal distributions was used to estimate the size of the more resistant subpopulation. Non-linear least squares regression was carried out using Solver in the Analysis Tool-Pak in Excel 2013. The software used for non-linear least squares regression was the generalized reduced gradient (GRG) nonlinear algorithm [6] incorporated in Microsoft (R) Excel 2013. Degree of improvement in the fit to the sum of two log-normal distributions was tested using both the F-test and the Akaike Information Criterion (AIC). Details are provided in S1 Appendix for non-linear least squares regression, the log-normal models tested, and the statistics used to assess quality of fits. At least 10 permutation runs were carried out for each non-linear least squares analysis. Typically, parameters derived from the permutation runs differed by a few percent among runs, and in all cases standard deviations of compiled parameter estimates were less than ten percent.

Risk of bias in individual studies & across studies

Individual studies may exhibit bias, since studies of antimicrobial resistance are often initiated because a problem is suspected or has been demonstrated by other means. That is, a hospital concerned that they are experiencing problems with onsite antimicrobial resistance are more likely to test for resistance. If no problem is suspected, there is limited inclination to launch such a study. This could bias outcomes by resulting in detection of more resistance than would be detected if studies were more evenly distributed to include facilities where no problem is suspected. The degree of bias this may introduce is extremely difficult to assess, although the increasing number of investigations infers indirectly that resistance is increasing with time.

Summary measures

Since this is not meta-analysis, summary measures such as risk-ratios or other measures based on summaries of data generated from individual reports were not used. Instead, individual MIC values were compiled across studies with MIC values for each particular species among the eight species included in the final analysis. Summary measures were derived by species to determine the time course of changes in CHX resistance using standard linear regression analysis and for detection of subpopulations within a species with differences in CHX susceptibility using non-linear least squares regression analysis, as described above and in S1 Appendix. Weighting in such models is dependent strictly on the number of MIC values included in the analysis. Thus, studies reporting many individual MIC values were weighted proportional to the number of MIC values for particular microbial species. When possible, analysis of means for subpopulations determined using non-linear least squares analysis were compared to CHX MICs for strains known to be resistant to clinically-relevant antibiotics. In several cases, as shown in detail below, strains with resistance to antibiotics were also resistant to CHX, although resistance to CHX was of low magnitude. It is important to keep in mind that such a result is correlative and not necessarily a demonstration of CHX causing antibiotic resistance.

Synthesis of results

No meta-analyses were used.

Additional analyses

The appearance of resistant strains are unlikely to occur en masse in any particular study but rather as a limited number of strains among a collection of non-resistant, strains. Therefore, techniques that attempt to reduce variability in a particular study, as is common in meta-analysis such as meta-regression, are inappropriate for analyses presented below. Such pooled variance-reducing analyses are likely to reduce or completely disguise detection of resistant strains in the mass of data collected for a particular species across numerous study reports.

Results

Ps. aeruginosa

One of the most important organisms with increasing resistance to clinical antibiotics is Pseudomonas aeruginosa. Thus, determining resistance to antiseptics, including CHX, is unusually important. Simple linear regression of MIC values using CHX susceptibilities of strains isolated over an 80 year time interval showed a slight increase in slope of the line (Fig 2).

Fig 2. Linear regression of log2(MIC) values over time for Ps. aeruginosa.

Fig 2

Values used in linear regression were from human clinical samples collected from approximately 1940 to 2016 (open circles). The dotted line is the linear regression line derived from the human clinical isolates. Small grey symbols are log2(MIC) values from non-clinical strains or strains isolated from animals and were not included in the linear regression shown. There are 523 log2(MIC) values compiled from 21 separate reports used in linear regression.

The results indicate a significant slope to the regression line corresponding to an increase in MIC values for CHX of 0.019 log2(MIC) units per year or approximately a 2-fold change for strains isolated over 50 years. The mean slope (± standard error of the mean, SEM) for linear regression was 0.019 (±0.0005) log2(MIC)/year using randomization of isolation dates and randomization of ~15% of the log2(MIC) values. The robustness of the linear regression is indicated by p-values associated with the F-tests of regression. The distribution of p-values, regression parameters and results of statistical tests are shown in S1 Fig and S1 Table in S2 Appendix.

Was the increase in resistance over time the result of a large number of strains with a low level of resistance or is there a small subpopulation of highly resistant strains? Additionally, was there a continuum of strains with gradually increased CHX resistance or were there discrete subpopulations with definable population parameters among the strains? To determine the distribution of resistance among Ps. aeruginosa strains, distributions were fitted to the log2(MIC) values (Fig 2), i.e. fitting log-normal distributions. The fit to the sum of two log-normal distributions was markedly better than the fit to a single log-normal indicating the presence of two subpopulations. The mean of the less-resistant subpopulation was 3.85 log2(MIC) units (~ 14 μg/ml). The second subpopulation indicated greater resistance to CHX with a mean of 4.81 (~ 28 μg/ml). Thus, two subpopulations of Ps. aeruginosa were detected including a subpopulation approximately 2-fold more resistant to CHX than the base subpopulation, which is consistent with values calculated from the linear regression time course. Non-linear least squares regression also provided an estimate of the relative number of strains associated with each subpopulation. The Ps. aeruginosa subpopulation associated with the higher mean value was approximately 62% of the 523 strains compiled for this report indicative of a large number of strains with a low level of increased CHX resistance. Detailed results of log-normal non-linear regression analyses are given in S2 Table in S2 Appendix.

Values for strains isolated prior to 1990 were pooled and analyzed. The pre-1990 results showed a single population parameter with mean value = 4.0 and a population standard deviation parameter = 0.88. The values are in reasonable agreement with the more susceptible mean and standard deviation parameters from the subpopulation of CHX log2(MIC) values over all dates shown in Fig 3 (mean = 3.85, standard deviation = 0.69). The small standard deviation indicated that the range of values over the population of strains isolated before 1990 was narrow (S3 Table in S2 Appendix). Log2(MIC) values for strains isolated after 1990 were pooled and analyzed separately. The post-1990 subpopulation was consistent with the sum of two log-normal distributions with population parameters in close agreement with the values from the analysis of all strains regardless of isolation date (S2 Fig and S4 Table in S2 Appendix). However, the post-1990 subpopulation showed that approximately 3/4s of the strains were consistent with the more resistant subpopulation of strains. Additionally, the standard deviation of the population was broad compared to the pre-1990 strains suggesting the presence of strains with a broader range of levels of resistance compared to the pre-1990 population.

Fig 3. Ps. aeruginosa with single log-normal (black dashed line) and sum of two log-normal distributions (red dashed line) fit to log2(MIC)s for 523 strains for all dates.

Fig 3

The summary of ten permutation runs is provided in S2 Table in S2 Appendix.

In summary, the pre-1990 strains are consistent with a single log-normal population, but the post-1990 population has both a subpopulation consistent with the pre-1990 strains and a second more resistant group of strains, approximately 76% of the total, with an increased resistance to CHX, albeit only an approximately 2-fold higher mean MIC. Summary parameter values associated with sub-populations are presented in Table 1.

Table 1. Population parameters for CHX susceptibility of Ps. aeruginosa.

Total population (all dates) Pre-1990 Post-1990
Mean 1 3.85 3.99 3.84
Std Dev 1 0.69 0.88 0.57
Mean 2 4.81 - 4.77
Std Dev 2 1.97 - 1.95
n2 322 (61.5%) A 124 (23.5%) A 301 (75.7%) B

All values are in log2(MIC) units.

A n is the number (%) of values among the 523 associated with Mean 2 and Std Dev 2, all isolation dates.

B n is the number (%) of values among the 400 associated with Mean 2 and Std Dev 2, post-1990.

Antibiotic resistance was reported by authors for 44 (8.4%) of the 523 strains evaluated from all isolation dates. Since 10 of the log2(MIC) values for the 44 antibiotic resistant strains were presented as MIC50s, 20 permutation runs were carried out to generate values in the range designated by authors [7]. The mean of the 20 permutation runs was 5.74 log2(MIC) units (SEM = 0.020) and the standard deviation of the 20 permutation runs was 2.41 log2(MIC) units (SEM = 0.011). Thus, the values for the antibiotic-resistant strains are most consistent with the values for the more resistant subpopulation of CHX strains isolated after 1990. Unfortunately, the number of values for antibiotic-resistant strains was not sufficient to support conclusive non-linear least squares regression analysis. Nevertheless, resistance to conventional antibiotics appeared to be associated with Ps. aeruginosa strains that were more resistant to CHX than were strains isolated before 1990.

K. pneumoniae

Another extremely important organism to characterize with respect to its CHX resistance is K. pneumoniae. The time course of susceptibility to CHX is shown in Fig 4. The slope of the linear regression line, 0.0300 ± 0.001 log2(MIC) units per year, indicated an increase in resistance of approximately 2.8-fold over 50 years.

Fig 4. Time course of K. pneumoniae susceptibility to CHX.

Fig 4

The results are from a single representative linear regression analysis from among 50 permutation runs. Details of linear regression parameters are given in S5 Table in S2 Appendix. Replicate permutations sampling within the range of uncertainties for isolation dates and MIC values as reported in the literature for the 21 studies compiled for this report indicated a small slope consistent with a small degree of decrease in susceptibility to CHX over the approximately 90 year time interval of isolation dates for K. pneumoniae strains.

The fit of a single or the sum of two log-normal distributions to the data (n = 714) indicated the presence of two subpopulations in the pooled data (S6 Table in S2 Appendix). One subpopulation had population parameters with mean = 3.90 log2(MIC) (population standard deviation = 0.54 log2(MIC) units). A more resistant subpopulation had population parameters with mean = 5.02 log2(MIC) units (population standard deviation = 1.98 log2(MIC) units). The log2(MIC) values correspond to 12 μg/ml and 32 μg/ml, respectively, i.e. 2.1-fold difference in resistance to CHX consistent with the degree of change noted from the linear regression time course. Results from a representative permutation run are shown in Fig 5. As was observed for Ps. aeruginosa strains, the population standard deviation of the more resistant subpopulation was also markedly broader than the population standard deviation for the baseline K. pneumoniae strains.

Fig 5. Comparison of fits by single and sum of two log-normal cumulative distribution functions to pooled K. pneumoniae data.

Fig 5

The improved fit of the sum of two log-normal distributions compared to a single log-normal was indicated by differences in AIC ranging from 11 to 68 and p-values for the F-test ranging from 1 x 10−5 to 1 x 10−3. See S6 Table in S2 Appendix for details.

Some of the reports identified strains with antibiotic resistance. In particular extended-spectrum beta-lactamase-resistant (EBSL) strains [8, 9], NDM-1 containing strains [10], carbapenem-resistant strains with sequence type ST258 [11], ST395 sequence type strains [12], ceftazidime-resistant strains [13], strains designated as ST147 [12], strains listed as carbapenem-resistant K. pneumoniae (CRKP) [9], and multi-drug resistant (MDR) strains [14] were reported with their corresponding MICs for CHX. A total of 205 CHX MIC values were listed for antibiotic-resistant strains among the studies included in this report. Pooled MICs found the mean (± Std Dev) for all of the antibiotic-resistant strains log2(MIC) values = 5.6 (± 1.6). The isolation years for the antibiotic-resistant strains ranged from 2006 to 2019, i.e. late in the time series presented in Fig 4. The mean (± Std Dev) for the strains not listed as antibiotic resistant, which were isolated in years from 1932 to 2019, was 4.6 (± 2.4). Permutation runs were used to generate data sets accounting for the uncertainty in 38 of 205 MICs for which MIC50s and MIC90s were reported in antibiotic resistant strains and 137 of 509 strains not listed as antibiotic-resistant. Student’s t-test with unequal variances (Welch’s test) found p-values ranging from 5 x 10−8 to 3 x 10−9 consistent with distinguishable differences in MICs between the two groups.

The permutation runs found very robust population parameters for antibiotic-resistant K. pneumoniae strains, as given in detail in S7 Table in S2 Appendix. The population of drug resistant strains is highly consistent with the presence of two log-normal subpopulations (S3 Fig and S7 Table in S2 Appendix). One subpopulation has a high parameter value, mean log2(MIC) = 7.4 (MIC = 55 μg/ml) with a relatively narrow subpopulation standard deviation = 0.8 log2(MIC) units. The more resistant subpopulation corresponds to approximately 71 (35%) of the 205 strains or 10% of the total 714 strains. The other strains making up approximately 65% (n = 134) of the drug-resistant population had mean and standard deviation parameters consistent with subpopulation parameters of mean = 4.6 and standard deviation = 1.1 only slightly elevated relative to the baseline subpopulation, mean = 3.9 log2(MIC) units which was not antibiotic resistant. Thus, similar to results from Ps. aeruginosa strains, there appears to be a correlation between conventional antibiotic resistance and CHX resistance, although the degree of CHX resistance was low.

A. baumannii

A. baumannii is another organism with increasing importance for infections because of the antibiotic resistance associated with many clinically important strains, especially strains isolated from hospitals. Prior to the 1990s, taxonomic classification of Acinetobacter was not uniform or well defined. The name A. baumannii was formally proposed and accepted in 1986 (see Peleg, et al. for a review of taxonomic and clinical features of the species [15]). As a result, there are no citations of A. baumannii strains isolated prior to that date. Tests of susceptibility to CHX for strains with isolation dates beginning in approximately 1999 are shown in Fig 6.

Fig 6. Time course of MICs for A. baumannii for strains from all isolation dates.

Fig 6

Individual log2(MIC) values are shown for the 1277 readings reported in the publications compiled for this report. A representative example of linear regression from among 50 permutation runs (dashed line) is shown superimposed on the individual measurements. The parameters for linear regression and details of statistical analyses are given in detail in S8 Table in S2 Appendix.

The average slope (± SEM) for the linear regression analyses was 0.11 (SEM = ± 0.0002) log2(MIC) units/year. The p-values for the F-test of linear regression model indicated extremely robust support for the linear regression fit to the data. The results indicated a mean reduction in susceptibility to CHX among A. baumannii strains of 2.18 log2(MIC) units or ~4.5-fold, a shift from approximately 16 μg/ml in the year 2000 to approximately 72 μg/ml projected from the data for the year 2020.

Considering the density of the data in the time interval from 2010 to 2017, the corresponding log2(MIC) values (n = 983) were analyzed separately from data with earlier isolation dates (S4 Fig and S10 Table in S2 Appendix). The average slope = 0.112 (SEM = ± 0.001) log2(MIC) units. The p-values for the F-tests of the linear regression model strongly support the conclusion that the slope of the line is positive with values nearly identical to the results from the data pooled from all isolation dates (S9 Table in S2 Appendix). Thus, the resistance to CHX appears to have increased across the entire time course considered here, including over the last decade.

To further analyze the A. baumannii MIC data, a single or the sum of two log-normal distributions was fitted to the log2(MIC)s. The results of non-linear least squares regression show that the distribution of log2(MIC) values is substantially more consistent with a sum of two log-normal distributions than with a single log-normal distribution (Fig 7 and S11 Table in S2 Appendix). The results are most consistent with a mean of approximately 2.83 log2(MIC) units (7.1 μg/ml) CHX for one subpopulation and a second subpopulation with a mean of approximately 5.30 log2(MIC) units (39 μg/ml) CHX, that is, a 5.5-fold decrease in susceptibility to CHX. The population with the higher MIC made up approximately two-thirds (69%) of the total population. The results are substantially in agreement with the results from linear regression.

Fig 7. Fits of a single log-normal and the sum of two log-normal distributions to MIC data from A. baumannii strains isolated on all dates.

Fig 7

Parameter values for the best fit are presented in the main text and details for the comparison of fits is given in S9 Table in S2 Appendix.

The data for MICs for strains isolated before 2010 were too sparse to analyze the sum of two log-normal distributions with confidence. However, the data are consistent with a single population with population parameters of mean = 3.2 log2(MIC) units (9.2 μg/ml) and standard deviation = 1.3 log2(MIC) units (n = 294, not shown), which is reasonably consistent with the lower sensitivity population in the MICs compiled from all dates, i.e. 7.1 μg/ml. The MICs observed using strains isolated in 2010 or later were also analyzed for the fit of a single or the sum of two log-normal distributions (S5 Fig and S11 Table in S2 Appendix). Similar to the results for linear regression of strains isolated between 2010 and 2017, fits of log-normal distributions to MICs observed after CHX treatment results were most consistent with two A. baumannii subpopulations, one with a subpopulation mean of 3.9 (Std Dev = 1.2) log2(MIC) units and a second subpopulation with mean of 5.8 (Std Dev = 0.8) (S5 Fig and S11 Table in S2 Appendix). The more CHX-resistant subpopulation has approximately the same population parameters as the more resistant subpopulation from the data pooled over the full time course, i.e. 1999–2017. The results are consistent with a greater concentration of CHX resistant strains after 2010.

More than 2/3s of the A. baumannii strains compiled with isolation dates of 2010 or later were designated by authors as multiple-drug resistant (MDR) (S12 Table in S2 Appendix). Analysis of subpopulations using fits to a single or the sum of two log-normal distributions indicate the presence of two subpopulations within the MDR strains with mean susceptibilities to CHX of 20 μg/ml and 66 μg/ml in good agreement with the values of 15 μg/ml and 55 μg/ml for all strains isolated from 2010 to 2017. This suggests that MDR strains are not necessarily also CHX-resistant.

E. coli

Another Gram-negative organism which has been tested for CHX susceptibility is E. coli. The broad range of MIC values reported for E. coli strains and linear regression of log2(MIC) values over time is shown in Fig 8. The average slope (± SEM) for time versus log2(MIC) was—0.035 (± 0.00004) log2(MIC) units. Details are provided in S13 Table in S2 Appendix. The biological significance of the negative slope of the linear regression line is uncertain but suggested an increase in CHX susceptibility of 1.7 log2(MIC) units over 50 years, i.e. a change of approximately 3-fold. The negative slope was particularly associated with strains isolated from humans in the time interval after 1990 with the slope = - 0.049 log2(MIC) units associated with human strains isolated after 1990. MICs for strains isolated from animals showed a positive slope of 0.036 log2(MIC) units (not shown). However, reports of E. coli strains from animals were concentrated with more than 80% from two studies [16, 17], so that interpretation of results from strains isolated from animals is limited by the small number of studies compiled for this report.

Fig 8. Time course of E. coli susceptibility to CHX over time.

Fig 8

A large number of E. coli strains (n = 2179) have been tested for susceptibility to CHX with results shown for strains isolated from as early as the 1940s. Linear regression indicated a negative slope of relatively low magnitude as shown by the dashed line. Parameters are given in the text and in S13 Table in S2 Appendix. Subpopulations of E. coli strains with different susceptibilities to CHX were not detected (S6 Fig, S14 Table in S2 Appendix). That is, no evidence was detected of a CHX-resistant subpopulation among more than 2000 strains evaluated.

Analyzing the log2(MIC) values reported for 45 antibiotic resistant strains, including carbapenem-resistant [18], extended spectrum beta-lactamase expressing cells [8], or strains expressing the New Delhi metallo-beta-lactamase [10], showed a mean (± Std Dev) of 4.14 (± 1.54) log2(MIC) units for the pooled antibiotic-resistant strains. This is different than the mean of all other strains (n = 2134) with mean = 1.81 (± 1.69) log2(MIC) units. The subpopulations were compared using Welch’s t-test and results were consistent with a substantial difference in susceptibility to CHX between the known antibiotic-resistant strains and the other E. coli strains (S15 Table in S2 Appendix). The magnitude of the difference between known antibiotic-resistant E. coli and the large number of other strains was approximately 5-fold.

The fit of a single log-normal distribution was very robust (S6 Fig and S14 Table in S2 Appendix). An equation with the sum of two log-normal distributions failed to converge indicating that the data are modeled very well using a single log-normal distribution with no evidence of the presence of a second log-normal subpopulation. This is despite the presence of 45 values for antibiotic resistant E. coli strains with mean = 4. 1 log2(MIC) units (S15 Table in S2 Appendix). This may indicate that the procedure is not sufficiently sensitive to detect a subpopulation with a small number of values, i.e. ~ 2% of the total 2179 values.

E. faecalis

The last Gram-negative organism included here is E. faecalis, another infectious agent frequently associated with antibiotic resistance, especially resistance to vancomycin. The time course of susceptibility to CHX is shown in S7 Fig and S16 Table in S2 Appendix. The slope of the linear regression line over 50+ years was negative suggesting a small decline in resistance to CHX, i.e. a reduction of -1.5 log2(MIC) units. The biological significance of the decrease is uncertain, especially since the data density is low.

The fit of log-normal distributions to CHX inhibition log2(MIC) values for E. faecalis were carried out for strains isolated from all dates collected for this report (S8 Fig and S17 Table in S2 Appendix). The results indicated the presence of two subpopulations with susceptibility to CHX of 5.0 μg/ml and 30 μg/ml.

The authors of reports containing E. faecalis data reported antibiotic resistance for 38 of the 276 MICs compiled here. The mean (± std dev) in log2(MIC) units for strains reported as VRE+, vancomycin-resistant, or qac+ = 2.0 (± 0.33), which is most consistent with the subpopulation with mean = 2.33 and not consistent with the sub-population with log2(MIC) = 4.9. However, the limited number of values reported for antibiotic-resistant strains makes interpretation of the data tentative. Resolution of this possible contradiction will require more data, although it is possible that the types of antibiotic resistance found in the strains analyzed here are not related to CHX resistance.

S. epidermidis

A Gram-positive species for which there is considerable concern regarding antibiotic resistance is S. epidermidis. The time course of MICs reported for CHX are shown in S9 Fig and S18 Table in S2 Appendix. The regression line had a slightly positive slope 0.005 (± 0.00004, SEM) log2(MIC) units/year. The p-values for the F-test of the fit of the linear regression model suggested no difference in susceptibility to CHX over time. Similarly, the fit of cumulative log-normal distributions to the S. epidermidis data indicated only for a single log-normal distribution (S10 Fig and S19 Table in S2 Appendix).

A study with analysis of a large number of S. epidermidis strains analyzed for susceptibility to CHX (n = 182) [19] found no relationship between prior exposure to CHX and the presence of qacA/B. Another study of S. epidermidis strains tested for CHX susceptibility [20] reported the presence of qacA/B in the strains with a reduced susceptibility to CHX. In all cases, the degree of increased resistance to CHX was low, typically a 2-fold shift. Considering the limited data available, the relationship between antibiotic resistance factors and susceptibility to CHX was not conclusive for S. epidermidis strains.

S. aureus

Perhaps the most important Gram-positive organism about which there are increasing concerns of antibiotic resistance is S. aureus. One of the most commonly applied discriminants of S. aureus strains is classification based on methicillin resistance. S. aureus strains reported as resistant to methicillin were analyzed separately from methicillin-sensitive strains.

As shown in Fig 9, linear regression of log2(MIC) values indicated a low magnitude negative slope for data from MRSA and MSSA strains consistent with a slight increase in susceptibility to CHX over time. (S20 and S21 Tables in S2 Appendix). The magnitude of the negative slopes is equivalent for both MRSA and MSSA strains; slope = -0.036 (SEM = ±0.0003) and -0.032 (SEM = ± 0.0002) log2(MIC) units, respectively. The slopes correspond to a decrease of -1.8 to -1.6 log2(MIC) units over 50 years, respectively, i.e. a decrease of 3.4-fold for MRSA and 3-fold for MSSA.

Fig 9. Susceptibility of S. aureus to CHX over time.

Fig 9

Two sets of results are shown: Strains specified as MRSA (dark blue open circles) and strains specified as MSSA (dark red open circles). Corresponding representative linear regression lines are shown as dashed lines in the same colors as the symbols. Details of linear regression analyses are given in S20 and S21 Tables in S2 Appendix.

Fitting cumulative log-normal distributions to the data indicated the presence of a single population for MSSA strains with population parameters mean = 0.23 and standard deviation = 1.33 log2(MIC) units. The fit of a sum of two log-normal distributions failed to converge on common values. No convincing evidence of a second subpopulation among MSSA strains was observed (S23 Table in S2 Appendix). The fit of a single cumulative log-normal distribution was sufficient to explain the data. Likewise, non-linear least squares regression for the fit of the sum of two log-normal distributions did not converge for the MRSA data, either (S22 Table in S2 Appendix). However, in comparison with results for MSSA strains, MRSA strains had population parameters of mean = 0.93 and standard deviation = 1.18 log2(MIC) units. Thus, MRSA strains showed a somewhat greater resistance to CHX than did MSSA strains, but both types of S. aureus strains showed no increase in CHX resistance over time. The difference between the MSSA and MRSA data indicated a mean of 1.2 μg/ml for CHX MICs from MSSA strains and a mean of 1.9 μg/ml for CHX MICs for MRSA strains, a 1.6-fold difference. Statistical analysis of MRSA and MSSA differences is illustrated in S11 Fig in S2 Appendix Text showing the distribution of t-test p-values for 100 permutation runs. Analysis of the pooled MRSA and MSSA results did not detect the presence of the two subpopulations. However, this is not surprising since the usual and predominant experimental process is the use of two-fold serial dilutions. Detection of a 1.6-fold difference when the resolution of the procedure is only 2-fold would not be expected.

C. albicans

A common fungal infectious agent is C. albicans, which has also been evaluated for increased antibiotic resistance. Susceptibility of C. albicans to CHX has been reported in a number of studies. A total of 1045 MICs were compiled to examine the pattern of CHX susceptibility over time. The slope of linear regression analysis over 50 permutation runs was robust with an average slope of -0.060 (SEM = ± 0.00009) log2(MIC) units. Examining the results after 1994 resulted in a similar regression coefficient = - 0.060 (not shown) indistinguishable from the estimate of the slope over the entire range of dates (S12 Fig and S24 Table in S2 Appendix). Thus, the negative slope was evident in the data collected over the last 25 years as well as the data over the entire time course, which is consistent with a small decrease in resistance to CHX over time for the pooled C. albicans strains.

The pooled log2(MIC) results (n = 1045) were analyzed for the fit of a single and the sum of two log-normal distributions. As shown in S13 Fig and S24 Table in S2 Appendix, there is strong evidence for the presence of two subpopulations within the strains compiled here. The sum of two log-normal distributions fit the data considerably better than did a single log-normal distribution. A more sensitive subpopulation had associated parameters of mean = 1.2 and standard deviation of 1.2 log2(MIC) units. The second subpopulation had population parameters of 3.3 and standard deviation of 0.59 log2(MIC) units. The more resistant sub-population was approximately 24% of the total 1049 strains.

The relationship between antibiotic-resistance and the subpopulations identified using log-normal distributions could not be evaluated for C. albicans. Only 4 strains among the 1045 for which CHX susceptibility was reported mentioned fluconazole resistance. Thus, it is possible that there is a relationship between the subpopulation with mean = 3.3 log2(MIC) units and antibiotic resistance, but the current data are not sufficient for a firm conclusion.

Discussion

The approach used above was to consider the strains of specific microbial species as populations to be analyzed using fundamental tools of statistics. In particular, linear regression was used to determine if there was evidence of changes in susceptibility to CHX over time. A second technique applied was analysis of microbial populations to observe the presence of subpopulations with different degrees of resistance to antimicrobials within a single species. Subpopulations based on differences in resistance to antibiotics have been derived, termed epidemiological cut-off values (ECOFFs), based on criteria that are relevant in clinical medicine [2124]. Similar methods have been applied in attempts to define ECOFFs for biocides [25]. The general concept is amenable for both antibiotics and biocides, although there are some important differences. In particular, biocides are typically used at concentrations that greatly surpass biocide resistance concentrations observed so far. Thus, in defining subpopulations of a microbial species that are resistant to biocides, the biological importance of the level of resistance observed is not clear. Nevertheless, a subpopulation with resistance greater than what was observed in a baseline subpopulation is useful for examining the potential threat of increased biocide resistance, which may also be associated with antibiotic resistance.

The relationship between resistance to antibiotics used in medicine and biocides used for disinfection in both medical and non-medical procedures has been the subject of many reports over the last 20 years (see as a few examples [3, 26, 27]). Despite considerable work, the relationship remains unclear. The work described here was intended to compile primary information in the form of MIC values for CHX reported in the literature over the last 50+ years covering as many organisms as possible. The primary question addressed evidence regarding the degree of susceptibility of various microorganisms to CHX, especially bacteria responsible for increasing numbers of human infections. An association with resistance to antibiotics commonly used in human clinical medicine was also described.

The statistical tool used previously to investigate subpopulations emphasized the use of probability density functions, e.g. the “bell-shaped curve” representative of a normal (Gaussian) distribution. Mathematically, either probability density or cumulative distribution functions can be used to describe populations. However, in contrast to the probability density form, properties of cumulative distribution functions may be more useful than probability density functions for characterization of microbe subpopulations with different antibiotic or biocide susceptibilities. This is particularly true for typical antimicrobial susceptibility testing which is based on the use of serial 2-fold dilutions. A major advantage favoring the use of cumulative probability functions is the lack of the need to place results in bins for analysis. Although most microbiological susceptibility testing has “natural” bins based on the 2-fold serial dilutions used, the serial dilution approach itself has problems, including variable accuracy across the range of concentrations tested. Some of the problems can be avoided or their effects reduced by the use of cumulative distribution functions, as described in S1 Appendix.

Linear regression indicated an increased average resistance to CHX in some species, although the change over several decades was small. Additionally, subpopulations with different CHX susceptibilities were found in several species, including Ps. aeruginosa, K. pneumoniae, and A. baumannii, and these correlated to various degrees with resistance to reported antibiotic resistance. A problem in many cases was that strains tested for CHX susceptibility were not necessarily well-characterized with regard to antibiotic resistance. For example, the two-fold change in average resistance to CHX in strains of Ps. aeruginosa over 50 years indicated by linear regression conformed to two distinguishable subpopulations detected using non-linear least squares analysis with mean subpopulation susceptibilities of 14 μg/ml and 28 μg/ml. In K. pneumoniae multi-drug resistant (MDR) strains expressing EBSL and NDM-1 a subpopulation mean MIC of 164 μg/ml for CHX was detected among approximately 10% of strains compared to the baseline susceptibility of 14 μg/ml. Perhaps the most remarkable change in CHX susceptibility was detected for A. baumannii with a 2-fold reduction in CHX susceptibility over 20 years. CHX resistance for a subpopulation of A. baumannii strains showed a mean of 66 μg/ml compared to the baseline susceptibility of 7 μg/ml. However, only approximately 35% of strains designated by study authors as MDR also showed the higher resistance to CHX, i.e. 66 μg/ml, indicating that antibiotic resistance only tracked partially with CHX resistance. For these three species there were variable degrees of correlation between CHX and antibiotic resistance.

The results for E. coli, E. faecalis, S. epidermidis, S. aureus, and C. albicans did not indicate a general increase in resistance to CHX over time. In fact the results were most consistent with a slight increase in susceptibility to CHX over time for four of the five species. Clinical relevance of the small difference is difficult to determine. The limited data on antibiotic resistance among strains tested for CHX susceptibility among these five species rendered firm conclusions about the relationship between CHX and antibiotic resistance difficult.

Clinical relevance of the degree of CHX resistance observed in all species considered here appears limited. Park, et al. [28] mentioned that CHX concentrations used in practice are 10–40 g/L, which is many-fold higher than the MICs reported for any microbes analyzed here. Otter, et al. [29] stated that “…higher MICs displayed by some isolates (4–16 mg/L) are still well below the effective chlorhexidine concentration applied to skin (10000–40000 mg/L) …” and cited two supporting reports. McGann, et al. [30] stated “In vitro studies of MIC and MBC with CHG demonstrate bactericidal action at levels well below recommended concentrations used in practice (2000 μg/ml).” Batra, et al. [31] may have provided some of the most direct evidence for CHX efficacy in the clinic despite the resistance to CHX associated with expression of qacA/B in S. aureus. Strains carrying qacA/B had in vitro susceptibility to CHX 3-fold less than non-qacA/B-carrying strains, but infections caused by the MRSA strains were equally suppressed using a sanitation protocol at typical CHX concentrations. Otter, et al. [31] restated that high levels of CHX are used in practice: “Nevertheless, the clinical impact of such a small MBC increase is debated, since the achieved concentration of topically applied CHDN 0.1% (wt/vol) solution will yield 1000 μg/ml, many fold higher than MBC of any qac- or smr- harboring strain.” It seems reasonable to conclude that the concentrations of CHX used routinely are considerably higher than those necessary to overcome the resistance to CHX reported so far. Nevertheless, the results indicate that vigilance with regard to the potential for increased resistance to CHX is warranted.

Does CHX use result in increased resistance to clinically relevant antibiotics? Wand, et al. characterized K. pneumoniae clinical isolates that were made resistant to CHX in vitro [32]. Five of six strains adapted to growth in CHX showed increased resistance to colistin, an antibiotic increasingly required in battling Klebsiella infection as an antibiotic of last resort. However, CHX resistance in the laboratory resulted from serial exposure to gradually increased concentrations of CHX, a condition apparently unlike the concentrations of CHX typically used. Are laboratory conditions used to generate CHX resistance sufficiently equivalent to conditions occurring in clinical or in food service or similar surface treatment applications to result in CHX resistance in places where the biocide is routinely used? The question remains open.

Understanding mechanisms of resistance to CHX and colistin may provide useful insights in addressing these questions. CHX potency on strains of K. pneumoniae isolated in the 1940s and 1950s prior to the widespread use of antibiotics [32, 33], were compared to more recently isolated strains [34]. Wand, et al. [32] and Shakib et al. [35] both reported similar patterns in expression of virulence and resistance factors with differences between pre-antibiotic and more recent strains supporting the idea that important virulence and resistance factors that were infrequently expressed in pre-antibiotic era K. pneumoniae strains are now commonly expressed. Although adaptive changes were reported after CHX treatment in vitro, the adaptations are not unique to CHX challenge. Surface-charge modifying mechanisms have been observed in several species of Gram-negative bacteria in response to membrane disruption challenges, including both CHX and polymyxins [3639]. Additionally, changes in expression of a number of efflux pump systems have been observed in response to membrane disruptive agents [3, 40]. However, it is still an open question whether resistance to colistin observed after in vitro CHX exposure is clinically relevant.

A. baumannii is unusual in its adaptability to membrane disrupting agents, including CHX. Powers & Trent [41] summarized: “Work done over the past 5 years has shown that Acinetobacter baumannii has the remarkable capability to survive with inactivated production of lipid A biosynthesis and the absence of LOS in its outer membrane.” Additionally, A. baumannii was the first organism noted to have inactivated lipid A biosynthesis in the presence of polymyxins apparently contributing to resistance. LOS-deficient A. baumannii strains were readily generated in vitro, but Powers and Trent concluded that isolation of such mutants in the clinic is “overwhelmingly rare” [41]. Are modifications induced by CHX treatment similar, i.e. inducible in the laboratory but very rare outside of it? Considering the remarkable resilience and adaptability of A. baumannii to a variety of conditions via a variety of mechanisms [42] it is not surprising that this adaptability results in some—so far indeterminate level of—resistance to CHX. A. baumannii clearly has particular and predominantly unique capacity for developing antimicrobial resistance. Nevertheless, resistance to CHX in A. baumannii appears to be rare and may be of limited clinical significance, especially when compared to concentrations of CHX typically used.

Sawyer, at al. [43] examined several LPS precursors and products within the synthetic pathway in E. coli when treated with a range of concentrations from 1/16 MIC to 8X MIC of a group of biocides and antibiotics, including triclosan, colistin, polymyxin B, fluroquinolones, penicillin analogues, aminoglycosides, CHX, CTAB, and the LpxC-inhibitor CHIR090. CHX treatment, in contrast to nearly every other agent tested, showed a significant accumulation of Lipid X, the 2-lipid-chain precursor of Lipid A consistent with pronounced inhibition at steps early in LPS synthesis. This mechanism appears unique compared to resistance mechanisms for other membrane disruptive agents which act via modifications of the charges on Lipid A [36, 38, 44, 45]. Thus, testing for resistant mutants with changes in early LPS synthesis seems particularly important in overall monitoring of resistance to CHX and perhaps other biocides.

Many changes in gene expression have been described after treatment with CHX. Ps. aeruginosa treated with 5 μg/ml chlorhexidine diacetate found 250 “statistically significant” changes in gene expression [46]. Genes with altered expression included efflux transporters and permeability-altering responses which also accompanied resistance to polymyxin B, gentamicin and EDTA. In the response of Salmonella to CHX a complex defense network was detected involving multiple cell targets associated with the synthesis of the cell wall, the SOS response, virulence, and a shift in cellular metabolism toward anoxic pathways [47]. Hashemi, et al. used serial exposure to generate Ps. aeruginosa strains resistant to 4–8 fold higher concentrations of CHX which also showed 8-32-fold increased resistance to colistin [48]. Proteomics was used to analyze the cross resistance and found that the changes occurred in proteins involved in LPS assembly in the outer membrane as well as in virulence factors. Expression of 330 of 528 proteins and colony morphology were changed consistent with changes in cell surface expression. Hashemi, at al. also stated, “Cross resistance of bacteria and colistin may be due to common features of these antimicrobials.” The results are largely consistent with the results observed by Nde, et al. [46], who measured transcription changes accompanying CHX exposure in Ps. aeruginosa, A. baumannii, and K. pneumoniae. Upregulation of microbial metabolism, carbon metabolism, ATP binding, nucleotide binding and protein translation were observed as was downregulation of proteins involved in nucleotide binding, ATP-binding, cytoplasm and phosphate-binding proteins. Expression of many membrane-associated proteins were also changed.

Such observations are particularly important in the context of work describing mutations in core metabolic genes as part of initial events conferring antibiotic resistance preceding induction of canonical resistance factors [49]. A critical question is whether the low-level CHX resistance observed so far will be modified into relevant high-level resistance mechanisms similar to the antibiotic canonical mechanisms. The low magnitude resistance to CHX described above compiled from observations of resistance over many years may indicate frequent modifications or mutants of cell surface and metabolic processes. Such mutations and/or changes in expression of metabolic and other physiological processes may be the major effect of CHX treatment leading to low-level resistance. The changes may also result in cross-resistance to clinically relevant antibiotics. Verification or refutation of this notion may best be accomplished by examining mutations and expression changes in metabolic pathways following CHX exposure and correlating the results with resistance to CHX and antibiotics.

A workshop held in Portugal in 2012 acknowledged “that there is scientific evidence that biocides select for biocide resistance, but that there is, so far, no conclusive evidence that this also determined or will determine an increase in antibiotic resistance” [50]. A critical but unanswered question is: Is there evidence that CHX induces increased susceptibility to colistin in the clinic or community? It is clear that CHX treatment can increase resistance to colistin in laboratory conditions, but this is not the same as demonstrating that this has happened in a clinically relevant setting. Caution in interpretation and transfer of laboratory findings to clinically relevant cases has been urged over the last 15 years [51, 52], a caution worth repeating.

The work described in this report may be useful in providing evidence of the need for a national or international registry of MIC values for CHX, in particular, and biocides in general. The compiled results presented here, i.e. in S3 Appendix, may serve as a starting point for such a database by providing what may be the largest compilation of such information assembled to date. Although at this time the development of well-documented ECOFFs or similar measures for biocides are tentative, a national or international database, if supplemented with new MIC values as they are published, could provide firm bases both for ECOFFs as well as acting as a monitor for changes in biocide resistance and potential cross-resistance with widely used antibiotics.

Supporting information

S1 Checklist. PRISMA 2009 checklist.

(DOC)

S1 Appendix. Statistics for analysis of minimum inhibitory concentration (MIC) data.

(DOCX)

S2 Appendix. Detailed species information.

S1 Table. Linear regression parameters, Ps. aeruginosa, all data. S1 Fig. Distribution of p-values (F-statistic) for slope parameters, Ps. aeruginosa all data. S2 Table. Log-normal parameters for Ps. aeruginosa, all dates. S3 Table. Log-normal parameters for Ps. aeruginosa, pre-1990. S4 Table. Log-normal parameters for Ps. aeruginosa, post-1990. S2 Fig. Fit of log-normal models to Ps. aeruginosa data, post-1990. S5 Table. Linear regression parameters, K. pneumoniae, all dates. S6 Table. Log-normal parameters for K. pneumoniae, all dates. S3 Fig. Fit of log-normal models to K. pneumoniae, antibiotic resistant strains. S7 Table. Log-normal parameters for K. pneumoniae, antibiotic resistant strains. S8 Table. Linear regression parameters, A. baumannii, all dates. S9 Table. Log-normal parameters for A. baumannii, all dates. S4 Fig. Time-course of log2(MIC) values for A. baumannii strains isolated from 2010–2017. S10 Table. Linear regression parameters, A. baumannii, 2010 to 2017. S11 Table. Log-normal parameters for A. baumannii strains isolated after 2010. S5 Fig. Fit of log-normal models to A. baumannii strains isolated after 2010. S12 Table. Log-normal parameters for A. baumannii multi-drug resistant strains isolated after 2010. S13 Table. Linear regression parameters, E. coli, all dates. S6 Fig. Fit of log-normal model to E. coli, all dates. S14 Table. Log-normal parameters for E. coli, all dates. S15 Table. Analysis of antibiotic-resistant E. coli strains. S7 Fig. Time-course of log2(MIC) values for E. faecalis strains, all dates. S16 Table. Linear regression parameters, E. faecalis, all dates. S17 Table. Log-normal parameters for E. faecalis, all dates. S8 Fig. Fit of log-normal model to E. faecalis, all dates. S9 Fig. Time-course of log2(MIC) values for S. epidermidis strains, all dates. S18 Table. Linear regression parameters, S. epidermidis, all dates. S10 Fig. Fit of log-normal model to S. epidermidis, all dates. S19 Table. Log-normal parameters for S. epidermidis, all dates. S20 Table. Linear regression parameters, S. aureus, MSSA. S21 Table. Linear regression parameters, S. aureus, MRSA. S22 Table. Log-normal parameters for S. aureus, MRSA. S23 Table. Log-normal parameters for S. aureus, MSSA. S11 Fig. Distribution of p-values (t-test) S. aureus MRSA vs MSSA. S24 Table. Linear regression parameters, C. albicans, all dates. S12 Fig. Time-course of log2(MIC) values for C. albicans strains, all dates. S13 Fig. Fit of log-normal models to C. albicans, all dates. S25 Table. Log-normal parameters for C. albicans, all dates.

(DOCX)

S3 Appendix. Raw data sources.

(XLSX)

Acknowledgments

Inspiration for this project rests significantly with two people, unfortunately now both are dead. The originator of the project was Milton Hinsch, Technical Services Director at Molnlycke. His interest as a microbiologist was to find the best information about potential resistance to CHX. The second person was a mentor to the author for about 20 years. Ferenc J. Kezdy was a consummate scientist who taught and emphasized the value of quantification in all things biological and chemical. The work reported here would not have been possible without this mentorship. A third person is also thanked as a friend and advisor over many years on topics in biostatistics, Tom Vidmar. Tom has been a teacher and an encouraging influence on this and many other projects over many years. Of course, decisions and choices regarding analyses contained in this work are solely the responsibility of the author.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This study was funded under a contract between Select Bio Consult, LLC and Molnlycke Health Care, Surgical Marketing, in Peachtree, GA. The url is: https://www.molnlycke.us/contact-us/. The contact person at Molnlycke is Jason Liles. Molnlycke is the manufacturer and marketer of products including formulations containing chlorhexidine. SB was contracted as an independent consultant employed by Select Bio Consult, LLC and has no other affiliation with Molnlycke or any of its affiliates. The funder provided support in the form of salaries for the author [SB], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Select Bio Consult, LLC is incorporated in Indiana and its sole owner and employee is Stephen Buxser, Ph.D. There are no additional relationships financial or non-financial between Select Bio Consult, LLC, Stephen Buxser, and Molnlycke Health Care.

References

  • 1.Davies GE, Francis J, Martin AR, Rose FL, Swain G. 1:6-Di-4′-Chlorophenyldiguanidohexane (“Hibitane”*). Laboratory Investigation of A New Antibacterial Agent of High Potency. British Journal of Pharmacology and Chemotherapy. 1954;9: 192–196. doi: 10.1111/j.1476-5381.1954.tb00840.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Karpinski TM, Szkaradkiewicz AK. Chlorhexidine—pharmaco-biological activity and application. European Review for Medical and Pharmacological Sciences. 2015;19: 1321–1326. [PubMed] [Google Scholar]
  • 3.Poole K. Mechanisms of bacterial biocide and antibiotic resistance. Journal of Applied Microbiology. 2002;92: 55S–64S. doi: 10.1046/j.1365-2672.92.5s1.8.x [DOI] [PubMed] [Google Scholar]
  • 4.Chapman JS. Biocide resistance mechanisms. International Biodeterioration & Biodegradation. 2003;51: 133–138. doi: 10.1016/S0964-8305(02)00097-5 [DOI] [Google Scholar]
  • 5.Ortega Morente E, Fernández-Fuentes MA, Grande Burgos MJ, Abriouel H, Pérez Pulido R, Gálvez A. Biocide tolerance in bacteria. International Journal of Food Microbiology. 2013;162: 13–25. doi: 10.1016/j.ijfoodmicro.2012.12.028 [DOI] [PubMed] [Google Scholar]
  • 6.Lasdon LS, Waren AD, Jain A, Ratner M. Design and Testing of a Generalized Reduced Gradient Code for Nonlinear Programming. ACM Trans Math Softw. 1978;4: 34–50. doi: 10.1145/355769.355773 [DOI] [Google Scholar]
  • 7.Ekizoğlu M, Sağiroğlu M, Kiliç E, Hasçelik AG. An investigation of the bactericidal activity of chlorhexidine digluconateagainst multidrug-resistant hospital isolates. Turk J Med Sci. 2016;46: 903–909. doi: 10.3906/sag-1503-140 [DOI] [PubMed] [Google Scholar]
  • 8.Goroncy-Bermes P, Brill FHH, Brill H. Antimicrobial activity of wound antiseptics against Extended-Spectrum Beta-Lactamase-producing bacteria. Wound Medicine. 2013;1: 41–43. doi: 10.1016/j.wndm.2013.05.004 [DOI] [Google Scholar]
  • 9.Guo W, Shan K, Xu B, Li J. Determining the resistance of carbapenem-resistant Klebsiella pneumoniae to common disinfectants and elucidating the underlying resistance mechanisms. Pathogens and Global Health. 2015;109: 184–192. doi: 10.1179/2047773215Y.0000000022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mal PB, Farooqi J, Irfan S, Hughes MA, Khan E. Reduced susceptibility to chlorhexidine disinfectant among New Delhi metallo-beta-lactamase-1 positive Enterobacteriaceae and other multidrug-resistant organisms: Report from a tertiary care hospital in Karachi, Pakistan. Indian Journal of Medical Microbiology. 2016;34: 346. doi: 10.4103/0255-0857.188338 [DOI] [PubMed] [Google Scholar]
  • 11.Naparstek L, Carmeli Y, Chmelnitsky I, Banin E, Navon-Venezia S. Reduced susceptibility to chlorhexidine among extremely-drug-resistant strains of Klebsiella pneumoniae. Journal of Hospital Infection. 2012;81: 15–19. doi: 10.1016/j.jhin.2012.02.007 [DOI] [PubMed] [Google Scholar]
  • 12.Muggeo A, Guillard T, Klein F, Reffuveille F, François C, Babosan A, et al. Spread of Klebsiella pneumoniae ST395 non-susceptible to carbapenems and resistant to fluoroquinolones in North-Eastern France. Journal of Global Antimicrobial Resistance. 2018;13: 98–103. doi: 10.1016/j.jgar.2017.10.023 [DOI] [PubMed] [Google Scholar]
  • 13.Zhou Z, Wei D, Lu Y. Polyhexamethylene guanidine hydrochloride shows bactericidal advantages over chlorhexidine digluconate against ESKAPE bacteria. Biotechnology and Applied Biochemistry. 2015;62: 268–274. doi: 10.1002/bab.1255 [DOI] [PubMed] [Google Scholar]
  • 14.Vijayakumar R, Sandle T, Al-Aboody MS, AlFonaisan MK, Alturaiki W, Mickymaray S, et al. Distribution of biocide resistant genes and biocides susceptibility in multidrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii—A first report from the Kingdom of Saudi Arabia. Journal of Infection and Public Health. 2018;11: 812–816. doi: 10.1016/j.jiph.2018.05.011 [DOI] [PubMed] [Google Scholar]
  • 15.Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3: 243–250. doi: 10.4161/viru.19700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sun Y, Hu X, Guo D, Shi C, Zhang C, Peng X, et al. Disinfectant Resistance Profiles and Biofilm Formation Capacity of Escherichia coli Isolated from Retail Chicken. Microbial Drug Resistance. 2019;25: 703–711. doi: 10.1089/mdr.2018.0175 [DOI] [PubMed] [Google Scholar]
  • 17.Aarestrup FM, Hasman H. Susceptibility of different bacterial species isolated from food animals to copper sulphate, zinc chloride and antimicrobial substances used for disinfection. Veterinary Microbiology. 2004;100: 83–89. doi: 10.1016/j.vetmic.2004.01.013 [DOI] [PubMed] [Google Scholar]
  • 18.Chen Y, Liao K, Huang Y, Guo P, Huang H, Wu Z, et al. Determining the susceptibility of carbapenem resistant Klebsiella pneumoniae and Escherichia coli strains against common disinfectants at a tertiary hospital in China. BMC Infectious Diseases. 2020;20: 88. doi: 10.1186/s12879-020-4813-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Skovgaard S, Larsen MH, Nielsen LN, Skov RL, Wong C, Westh H, et al. Recently introduced qacA/B genes in Staphylococcus epidermidis do not increase chlorhexidine MIC/MBC. Journal of Antimicrobial Chemotherapy. 2013;68: 2226–2233. doi: 10.1093/jac/dkt182 [DOI] [PubMed] [Google Scholar]
  • 20.Hijazi K, Mukhopadhya I, Abbott F, Milne K, Al-Jabri ZJ, Oggioni MR, et al. Susceptibility to chlorhexidine amongst multidrug-resistant clinical isolates of Staphylococcus epidermidis from bloodstream infections. International Journal of Antimicrobial Agents. 2016;48: 86–90. doi: 10.1016/j.ijantimicag.2016.04.015 [DOI] [PubMed] [Google Scholar]
  • 21.Beloeil PA. The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food for 2009. [Google Scholar]
  • 22.Marchese A, Esposito S, Barbieri R, Bassetti M, Debbia E. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections? BMC Infectious Diseases. 2012;12: 181. doi: 10.1186/1471-2334-12-181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kahlmeter G. The 2014 Garrod Lecture: EUCAST–are we heading towards international agreement? Journal of Antimicrobial Chemotherapy. 2015;70: 2427–2439. doi: 10.1093/jac/dkv145 [DOI] [PubMed] [Google Scholar]
  • 24.Kronvall G, Smith P. Normalized resistance interpretation, the NRI method. APMIS. 2016;124: 1023–1030. doi: 10.1111/apm.12624 [DOI] [PubMed] [Google Scholar]
  • 25.Morrissey I, Oggioni MR, Knight D, Curiao T, Coque T, Kalkanci A, et al. Evaluation of epidemiological cut-off values indicates that biocide resistant subpopulations are uncommon in natural isolates of clinically-relevant microorganisms. PloS one. 2014;9: e86669–e86669. doi: 10.1371/journal.pone.0086669 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Russell AD. Do Biocides Select for Antibiotic Resistance?*. Journal of Pharmacy and Pharmacology. 2000;52: 227–233. doi: 10.1211/0022357001773742 [DOI] [PubMed] [Google Scholar]
  • 27.Zamudio R, Oggioni MR, Gould IM, Hijazi K. Time for biocide stewardship? Nature Microbiology. 2019;4: 732–733. doi: 10.1038/s41564-019-0360-6 [DOI] [PubMed] [Google Scholar]
  • 28.Park K-H, Jung M, Kim DY, Lee Y-M, Lee MS, Ryu B-H, et al. Effects of subinhibitory concentrations of chlorhexidine and mupirocin on biofilm formation in clinical meticillin-resistant Staphylococcus aureus. Journal of Hospital Infection. 2020;106: 295–302. doi: 10.1016/j.jhin.2020.07.010 [DOI] [PubMed] [Google Scholar]
  • 29.Otter JA, Patel A, Cliff PR, Halligan EP, Tosas O, Edgeworth JD. Selection for qacA carriage in CC22, but not CC30, methicillin-resistant Staphylococcus aureus bloodstream infection isolates during a successful institutional infection control programme. Journal of Antimicrobial Chemotherapy. 2013;68: 992–999. doi: 10.1093/jac/dks500 [DOI] [PubMed] [Google Scholar]
  • 30.McGann P, Kwak YI, Summers A, Cummings JF, Waterman PE, Lesho EP. Detection of qacA/B in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus from a Regional Healthcare Network in the Eastern United States. Infection Control & Hospital Epidemiology. 2015/01/02 ed. 2011;32: 1116–1119. doi: 10.1086/662380 [DOI] [PubMed] [Google Scholar]
  • 31.Batra R, Cooper BS, Whiteley C, Patel AK, Wyncoll D, Edgeworth JD. Efficacy and Limitation of a Chlorhexidine-Based Decolonization Strategy in Preventing Transmission of Methicillin-Resistant Staphylococcus aureus in an Intensive Care Unit. Clinical infectious diseases. 2010;50: 210–217. doi: 10.1086/648717 [DOI] [PubMed] [Google Scholar]
  • 32.Wand ME, Bock LJ, Bonney LC, Sutton JM. Mechanisms of Increased Resistance to Chlorhexidine and Cross-Resistance to Colistin following Exposure of Klebsiella pneumoniae Clinical Isolates to Chlorhexidine. Antimicrob Agents Chemother. 2017;61: e01162–16. doi: 10.1128/AAC.01162-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Baker KS, Burnett E, McGregor H, Deheer-Graham A, Boinett C, Langridge GC, et al. The Murray collection of pre-antibiotic era Enterobacteriacae: a unique research resource. Genome Medicine. 2015;7: 97. doi: 10.1186/s13073-015-0222-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wand ME, Baker KS, Benthall G, McGregor H, McCowen JWI, Deheer-Graham A, et al. Characterization of Pre-Antibiotic Era Klebsiella pneumoniae Isolates with Respect to Antibiotic/Disinfectant Susceptibility and Virulence in Galleria mellonella. Antimicrob Agents Chemother. 2015;59: 3966. doi: 10.1128/AAC.05009-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Shakib P, Kalani MT, Ramazanzadeh R, Ahmadi A, Rouhi S. Molecular detection of virulence genes in Klebsiella Pneumoniae clinical isolates from Kurdistan Province, Iran. Biomed Res Ther. 2018;5: 2581–2589. doi: 10.15419/bmrat.v5i8.467 [DOI] [Google Scholar]
  • 36.Trent MS, Ribeiro AA, Doerrler WT, Lin S, Cotter RJ, Raetz CRH. Accumulation of a Polyisoprene-linked Amino Sugar in Polymyxin-resistant Salmonella typhimurium andEscherichia coli STRUCTURAL CHARACTERIZATION AND TRANSFER TO LIPID A IN THE PERIPLASM. J Biol Chem. 2001;276: 43132–43144. doi: 10.1074/jbc.M106962200 [DOI] [PubMed] [Google Scholar]
  • 37.Jayol A, Poirel L, Brink A, Villegas M-V, Yilmaz M, Nordmann P. Resistance to Colistin Associated with a Single Amino Acid Change in Protein PmrB among Klebsiella pneumoniae Isolates of Worldwide Origin. Antimicrob Agents Chemother. 2014;58: 4762. doi: 10.1128/AAC.00084-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Bishop R. E., Gibbons H. S., Guina T., Trent M. S., Miller S. I., Raetz C. R. Transfer of palmitate from phospholipids to Lipid A in outer membranes of Gram-negative bacteria. EMBO Journal. 2000;19: 5071–5080. doi: 10.1093/emboj/19.19.5071 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Shah NR, Hancock REW, Fernandez RC. Bordetella pertussis Lipid A Glucosamine Modification Confers Resistance to Cationic Antimicrobial Peptides and Increases Resistance to Outer Membrane Perturbation. Antimicrobial Agents and Chemotherapy. 2014;58: 4931–4934. doi: 10.1128/AAC.02590-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. Clinical Microbiology and Infection. 2004;10: 12–26. doi: 10.1111/j.1469-0691.2004.00763.x [DOI] [PubMed] [Google Scholar]
  • 41.Powers MJ, Trent MS. Expanding the paradigm for the outer membrane: Acinetobacter baumannii in the absence of endotoxin. Molecular Microbiology. 2018;107: 47–56. doi: 10.1111/mmi.13872 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Roca Subirà I, Espinal P, Vila-Farrés X, Vila Estapé J. The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol. 2012;3. doi: 10.3389/fmicb.2012.00148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sawyer WS, Wang L, Uehara T, Tamrakar P, Prathapam R, Mostafavi M, et al. Targeted lipopolysaccharide biosynthetic intermediate analysis with normal-phase liquid chromatography mass spectrometry. PLOS ONE. 2019;14: e0211803. doi: 10.1371/journal.pone.0211803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lee M, Sousa MC. Structural Basis for Substrate Specificity in ArnB. A Key Enzyme in the Polymyxin Resistance Pathway of Gram-Negative Bacteria. Biochemistry. 2014;53: 796–805. doi: 10.1021/bi4015677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wang X, Quinn PJ. Lipopolysaccharide: Biosynthetic pathway and structure modification. Progress in Lipid Research. 2010;49: 97–107. doi: 10.1016/j.plipres.2009.06.002 [DOI] [PubMed] [Google Scholar]
  • 46.Nde CW, Jang H-J, Toghrol F, Bentley WE. Global Transcriptomic Response of Pseudomonas aeruginosa to Chlorhexidine Diacetate. Environ Sci Technol. 2009;43: 8406–8415. doi: 10.1021/es9015475 [DOI] [PubMed] [Google Scholar]
  • 47.Condell O, Power KA, Händler K, Finn S, Sheridan A, Sergeant K, et al. Comparative analysis of Salmonella susceptibility and tolerance to the biocide chlorhexidine identifies a complex cellular defense network. Front Microbiol. 2014;5. doi: 10.3389/fmicb.2014.00373 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Hashemi MM, Holden BS, Coburn J, Taylor MF, Weber S, Hilton B, et al. Proteomic Analysis of Resistance of Gram-Negative Bacteria to Chlorhexidine and Impacts on Susceptibility to Colistin, Antimicrobial Peptides, and Ceragenins. Front Microbiol. 2019;10. doi: 10.3389/fmicb.2019.00210 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lopatkin AJ, Bening SC, Manson AL, Stokes JM, Kohanski MA, Badran AH, et al. Clinically relevant mutations in core metabolic genes confer antibiotic resistance. Science. 2021;371: eaba0862. doi: 10.1126/science.aba0862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Oggioni MR, Furi L, Coelho JR, Maillard J-Y, Martínez JL. Recent advances in the potential interconnection between antimicrobial resistance to biocides and antibiotics. Expert Rev Anti Infect Ther. 2013;11: 363–366. doi: 10.1586/eri.13.16 [DOI] [PubMed] [Google Scholar]
  • 51.Wales AD, Davies RH. Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens. Antibiotics. 2015;4: 567–604. doi: 10.3390/antibiotics4040567 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Russell A. Biocide use and antibiotic resistance: the relevance of laboratory findings to clinical and environmental situations. The Lancet Infectious Diseases. 2003;3: 794–803. doi: 10.1016/s1473-3099(03)00833-8 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Amal Al-Bakri

23 Apr 2021

PONE-D-20-37954

Has resistance to chlorhexidine increased among clinically-relevant bacteria? A systematic review of time-course and subpopulation data

PLOS ONE

Dear Dr. Buxser,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This is an  importance piece of work  and had a great value for the scientific population. Nevertheless, the paper is lengthy and should be shortened. Moreover, a major revision on the clarity of the methodology and results should be performed. 

Please submit your revised manuscript by Jun 04 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Amal Al-Bakri

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please confirm that you have included all items recommended in the PRISMA checklist including evaluating the risk of bias for the included studies and limitations of your study.

3. Thank you for stating the following in the Financial Disclosure section:

"This study was funded under a contract between SB and Molnlycke Health Care,

Surgical Marketing, in Peachtree, GA. The url is: https://www.molnlycke.us/contact-us/

The contact person at Molnlycke is Jason Liles. Molnlycke is the manufacturer and

marketer of products including formulations containing chlorhexidine. SB was

contracted as an independent consultant and has no other affiliation with Molnlycke or

any of its affiliates.

The funders had no role in study design, data collection and analysis, decision to

publish, or preparation of the manuscript."

We note that you received funding from a commercial source: Molnlycke Health Care.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

4. Thank you for stating the following in the Competing Interests/ section:

"I have read the journal's policy and the authors of this manuscript have the following

competing interests:SB was funded as an independent contractor by Molnlycke Health

Care, USA. Independence stipulated that Molnlycke had no role in study design, data

collection and analysis, decision to publish, or preparation of the manuscript."

We note that one or more of the authors are employed by a commercial company: Select Bio Consult, LLC.

4.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

4.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Dr Buxser

Many thanks for the opportunity to review your work. This is a critically important field of work and your report has the potential to deliver important information to health professionals and policy makers.

Below I have provided some feedback which I hope that you find helpful for improving your manuscript.

Overall, I feel that the manuscript is too long. At present, I estimate that the article is >12,000 words. I fully appreciate that systematic reviews are typically longer than other manuscripts, but they rarely exceed 5000 words.

Intro

The 1st paragraph feels a little disjointed. I'm not sure lines 48-52 add important content. Could you replace these lines with (for example) the structure of the molecule and how it works against microbes, the prevalence of use in surgery / food preparation, it's major pros and cons/safety concerns, etc?

Overall, I feel the introduction would benefit from truncation, by at least half. The paragraphs concerning MICs could be summarised in to a few sentences at most - interested readers can look elsewhere if needed, or more likely, will know this information.

The final paragraph of the introduction feels more like methods - you're outlining reporting issues in studies you have included and how you plan to drawn these terms/stats together. I think this should live in the analysis part of the methods.

Methods

Please revamp the presentation of your methods, headings, etc to comply with the PRISMA guidelines - I see that you've supplied this checklist but marked many of the sections N/A. I recommend following this checklist and organising your report as such. Additionally, the Cochrane Handbook is freely available and defines how reviews should (ideally) be laid out and what content is required, etc. At present, the order is unconventional/confusing as you present your statical methods first, without describing what you're analysing in who/what/where?

The definitions could be removed as these could be considered tacit amongst readers of this work.

Lines 146-152 could be summarised into 1 sentence with a reference. If readers don't know what permutation is then they can look at your reference / search elsewhere.

Line 155 "...which were typically in the range of p << 0.00001 and often in the 156 range of 10^-10 or smaller" could be shortened to "...which were typically 10^-10 or smaller"

Lines 159-162 these looks like results? Please consider moving them

Line 217 - This is your first description of the work as "systematic" but the search has many problems & is missing important information. Overall, the search description is too verbose. The 2 searches you describe should be summarised into 1 search / redone for your revised manuscript. I recommend the NICE Health Care Database (https://hdas.nice.org.uk/) as it's user friendly, covers all the important databases and allows you to export search results in numerous formats (.bib for reference managers, word, pdf, etc). What was the lower bound of the 1st search dates (database inception, 1970, 1980, 2011)? Science Direct is not a database per se, it is merely the engine for searching other databases. At present, you're missing some important databases from your 1st search including EMBASE and clinicaltrials.gov which are considered the absolute minimum. Your 2nd search looks much more comprehensive. The supplemental searches on Google Scholar and other non-indexed databases are fine to include. The differing strategies are likely to introduce biases of selection between pre-2012 and 2013-2018 hits. How many hits did your searches find in total? How many people screened the titles & abstracts? Normally, screening of studies is performed by at least 2 independent researchers to prevent error/misses, etc - was this done? If not, I recommend that an additional author joins the team.

What software did you use for your analyses? And what code was used to regress the data? I can't see how you've handled the variance of the aggregate data.... Normally, you'd apply meta-regression techniques for aggregate data (e.g. the metafor package in R or metan/metareg packages in Stata, etc) rather than simple OLS/NLLS regression. Simple regression techniques fail to account for differences in study prevision (e.g. large studies have a small variance and thus, could/should have more weight in the model), ignore potential sources of heterogeneity, etc.

Results

Figure 1 (row 1) is incomplete

The 2nd paragraph of the results should sumamrise the included studies. Human? Adults? Time spans? Countries? Settings? Population screening vs. surgical samples? etc etc. Brevity is key

I see no value in Fig3/22

Was the risk of bias assessed for included studies? This is normal in systematic reviews and should be presented in the results too.

Each section for each microbe could be significantly shortened to improve readability.

I love the scatter plots of MIC vs year with fitted lines - however, I'd like to see these from meta-regression instead. Could you colour the dots by concentration of CHX or delivery format or source (skin, blood, nasal, etc)?

I'm sorry but I don't understand that Figs 4/5/7/8/11/12/14/16/18/20/21/24

24 figures is too many - please select the most useful few (e.g. 6) for the manuscript - the rest can be supplementary.

Discussion

I haven't commented on the discussion content as I imagine this may change substantially in a revision.

I sincerely hope these comments help you to refine this important work and I'd be delighted to review a revision.

With thanks and best wishes for 2021

Reviewer #2: Has resistance to chlorhexidine increased among clinically-relevant bacteria? A systematic review of time-course and subpopulation data

Comments for Manuscript Number PONE-D-20-37954

A meta-analysis study that looks at time-course development of resistance/changes in susceptibility to CHX by looking at reported MIC values in the literature for nosocomial microorganisms. Also, the author attempted to address the degree of susceptibility to the association with antibiotic resistance.

A very comprehensive study was conducted by the author and a very large subset of data gathered from published studies was analyzed, using various statistical approaches.

There are increasing reports on antibiotic resistance / multi-drug resistance, however, there is still little work done on disinfectant and or biocide resistance. Nor is there much reports on correlating antibiotic and biocide resistance. The mechanisms of biocide resistance remain unclear, although reports state that the mechanisms are similar to antibiotic resistance. The current paper “zooms” out and gathers numerous data on CHX resistance, and draws a time-line indicating how the MIC of CHX is increasing over time. A very relevant and necessary study, and novel indeed. I do agree with the authors on a national registry for MIC values, this will allow the monitoring of microbial resistance development.

However, the review in itself was difficult to assess, as firstly the paper is rather lengthy, and it could be shortened, and there is a disconnect between the methodology and the results.

Line 70-72, gives a timeline for measurement of CHX susceptibility and resistance for the particular study, dating back 20-50 years, however, literature searches included in the final analysis (line 228-246) are between 2013-2020, from which the data presented in this paper is compiled. This is misleading, the author should clearly state (which was later referred to), that the isolates date back in some of the studies 20-50 years, date of isolation. If there is literature stating that exposure to CHX dates back 20-50 years than this should be referred to / or the strains are all CHX susceptible. If so, this should be a search parameter in the data filtering.

The dates for the research papers assessed/included and the dates for the reporting of results also do not correlate. I might have missed this (maybe it has been reported on in the supplementary material), but this brings in an element of confusion. Line 270 reports on MIC values reported over an 80 year time interval, also depicted in Figure 2, but the methodology does not indicate the inclusion of sources for these earlier timelines, as filtering was applied to the literature searches to eventually only include papers that met the parameters set.

Gathered from the data, and I could be wrong, as I am not a statistician, it seems different statistical parameters were applied to the different subsets of data representing the different microbial populations. Seemingly creating statistical bias.

Line 197-203; (in short), the number of permutation runs, and comparison of parameter values from the number of runs, as an estimator of result stability. The number of permutation runs was 80, according to this section. However, for some microbial organisms, more permutation runs were performed, see Table 1; 100 permutations runs were performed for P. aeruginosa. It appears that the introduction of variability was not kept to a minimum.

Although mentioned, there is some disconnect between the methodology, results and discussion, regarding CHX and colistin, this is, however, extensively discussed in the discussion. However, the use of colisitin coinciding with CHX use was not listed as an inclusion criterion, and the author does not mention why this particular antibiotic is of interest.

Editorial suggestions:

Line 228-246, can be combined and this section can be shortened.

How data is presented in figures can be improved, especially in figure 19, where MSSA and MRSA S. aureus are indicated (the author did use colors), but a better presentation would be different shapes (e.g. triangles and circles). This goes for the majority of the graphs, the presentation makes it difficult to follow.

The extensive information given in the section from line 252-266, should be kept to the relevant microbial organisms discussed in the paper. Line 264 seems misleading as the author refers to data compilation extending over 20 years, but based on the inclusion and exclusion criteria for the literature searches, the published data used does not date that far back.

The author made a great effort to discuss the relationship between CHX and antibiotic resistance, in this case, colistin. The discussion can be shortened, and some general information should be given, e.g. why the relationship of CHX and colistin was looked at, etc. This type of information might not necessarily be self-evident.

Ps. aeruginosa vs P. aeruginosa? I am not aware of the use of Ps.aeruginosa, if this is correct then I accept.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Review.pdf

PLoS One. 2021 Aug 19;16(8):e0256336. doi: 10.1371/journal.pone.0256336.r002

Author response to Decision Letter 0


18 Jun 2021

PLoS ONE Response to reviewers PONE-D-20-37954

Responses to Reviewer #1:

I appreciate your time and effort in reviewing this long and complicated manuscript and will address your comments, which led to a more succinct and readable version.

The major the reason that the manuscript is long is that it covers eight organisms in detail. Many authors would split the manuscript into at least two manuscripts and possibly four or even eight. This would diminish the impact because the goal was not simply to catalogue a list of changes observed using CHX but also to show the relationships observed among the organisms. It is particularly noteworthy that subpopulations across species have changes in resistance to CHX of similar magnitude, specifically of low magnitude markedly less than the concentrations of CHX used routinely. The point is best made in presenting results from the various microorganisms in a single document. Additionally, the relationships between resistance to antibiotics used clinically and resistance to CHX have both similarities and differences among the organisms. Nevertheless, the manuscript was shortened by removing many figures and tables most of which were moved to Supplemental Materials. Since the goal was to cover as many organisms as possible based on sufficient data to draw conclusions, it was not possible to justify commenting on all of the organisms without providing the data and detailed results of analyses somewhere.

Definitions were removed or a few were moved to Supplemental Materials, although the readership may be more broad than medical microbiologists for whom some definitions might be “tacit”. Interest in CHX and potential complications of its use extend to food scientists, supervisors of medical facilities, and many others unfamiliar with experimental microbiology and statistical techniques, especially the use of randomization to assess variance and numerical validity. Omitting all explanatory definitions would likely be a disservice to the potential broader audience.

Overall, the manuscript was rewritten, including the introduction, methods, results, discussion and Supplemental Materials. I hope you find the introduction more focused. The Methods section was restructured completely to conform substantially to the structure suggested in the 2009 PRISMA statement for reporting systematic reviews and meta-analyses. Many details were moved to the Supplemental Materials. Comments regarding original manuscript lines 146-162 were addressed in the revisions.

The next paragraphs address comments beginning about line 217 (prior manuscript version).

An essential point to note is that the approach used in the manuscript in both the original and revised form is not and was not intended to be a meta-analysis. It should be noted that the rest of the title of the PRISMA statement is “… that evaluate health care interventions….” [Liberati, et al. (2009) J Clin Epidemiol 62: e1-e34]. The data presented in this systematic review are not about health care interventions, as would be applicable for a drug or other medical treatment or intervention. It is a summary of primary data based strictly on direct laboratory measurements, although there are possible practical applications in clinical medicine. A major difference between what is presented in the manuscript and meta-analysis is that summary statistics, such as odds-ratios, logistic models, incidence rates, or analyses requiring multivariate analysis within individual reports are used in meta-analysis. In the current manuscript summary statistics are derived from the raw data as complement to and in some ways the converse of meta-analysis. In using raw data the approach taken here was fundamentally different than meta-analysis and requires a fundamentally different approach for useful analysis. This was apparently not adequately pointed out in the earlier manuscript, but has now been emphasized in a number of places in the revised manuscript (e.g. lines 88-91, 204-213, 221-226). As was noted in a publication describing meta-analysis [NG Berman and RA Parker (2002) Meta-analysis: Neither quick nor easy. BMC Medical Research Methodology 2:10] “A meta-analysis also differs from a ‘pooled data’ analysis because the summary results of the previous studies, not the results on individual subjects, are combined for analysis.” This distinguishes what the manuscript contains, i.e. pooled data, in contrast to meta-analysis. Similarly, Shelby and Vaske [(2008) Understanding meta-analysis: A review of the methodological literature. Leisure Sciences 30: 96-110] described in detail that meta-analysis is about combining effect sizes from individual studies, not about combining raw data from individual studies. The statistics specified for use in meta-analysis are designed especially to adjust for the quality of summary study results, not individual measurements. The process is used to account for and minimize effects of variance by weighting summary measurements inversely with variance [see E Ahn and H Kang (2018) Korean Journal of Anesthesiology 71(2): 103-112. N Mikolajewicz and SV Komarova (2019) Meta-analytic methodology for basic research: A practical guide. Frontiers in Physiology 10: article 203]. In pooling data from multiple studies, especially with regard to characterizing effects of CHX on individual strains as a population of strains within a species, minimizing variance would reduce or minimize the ability to detect strains with properties different than the majority of strains. The goal of the data analyses provided in this manuscript was to detect and quantify strains with particular CHX susceptibilities and to quantify the proportion of altered strains compared to baseline/unaltered subpopulations. Application of statistical methods minimizing variance as is done with meta-regression and similar statistical techniques applicable to meta-analysis would hide exactly the results of greatest interest and importance. I hope that the revised manuscript makes this essential distinction clear.

In deciding which data from which articles to include, there is a profound difference between meta-analysis and this systematic review of primary data. Screening articles to include in the meta-analysis requires judgment of whether the studies to be included were designed to address a similar enough question and contained similar enough measures of a treatment or intervention to allow combining the results into a new synthesis, the meta-analysis. In contrast, the systematic review process used here was simply to find CHX MIC values from in vitro assays. Judgement of studies to include differ broadly between the two approaches. The limited judgement required to find MIC values in a report that have been presented as numbers for individual microbial strains is much more straight-forward than trying to determine if treatment protocols and associated medical summary measurements are similar enough to combine. Meta-analysis necessarily should deal with issues of the quality of the various studies under consideration, but an assembly of raw MIC values requires no quality judgement beyond the similarity of in vitro measures of MIC determinations, which is a highly standardized experimental protocol. Importantly, a study reporting 100 CHX MICs for a particular organism will be weighted 10-fold more than a study reporting only 10 CHX MICs, which is an appropriate form of weighting for individual measurements like MICs and has the advantage of using the raw data rather than summary measures. One could construct summary measures, such as the mean and SEMs for CHX MIC values contained in a single report, but ignoring the raw data would complicate the analysis in an unnecessary and highly undesirable manner. In keeping with a systematic review uncomplicated by what is needed in meta-analysis, the raw MIC values were compiled across studies into a common pool. A second author/reviewer of the search results would add little to the process.

Comments regarding search methods and databases:

Ideally a search would use all possible databases and broad-ranging search terms to capture every possible instance of, in this case, an MIC for CHX. Of course this is a practical and financial impossibility. Many of the databases in routine use are expensive and available predominantly to academic researchers or employees of large companies who do not individually bear the costs. Moreover, searches are most often limited to the particular subscriptions provided by a library at a particular institution. Resources are used that authors have access to and tend to favor what they are familiar with. Restricting searches by use of relatively narrow search terms, i.e. a couple forms of chlorhexidine and likely terms for MICs, and restricting searches to titles and abstracts had the desired effect of locating a large number of studies with an emphasis on collections of MICs for CHX. By an admittedly difficult to verify method, i.e. checking for missed studies using review articles, no major studies missed in the searches were found. As listed in Table S2 of Appendix A, the minimum number of MICs used in analyses in this report was 276 from 16 reports of strains isolated from approximately 1970 to 2010 (E. faecalis section of Appendix B) and the maximum was 3585 MIC values for S. aureus from 24 reports with strains isolated from the 1930s to approximately 2018 (Table A2, Appendix A and S. aureus section of Appendix B). The median number of MICs used was 930 from the median of 20 studies. How is one to judge how thorough the search results are? How is one to assess “bias”? Despite statements suggesting that searches must be optimized and bias minimized, no systematic and verifiable method for assessing bias has been put forward. There are no studies that provide anything more than highly restricted snapshots of specific searches for a few topics (see for example: Kwon, et al. (2014) Systematic Reviews 3: 135; Falagas, et al. (2008) FASEB Journal 22: 338-342; Lam, et al. (2018) Journal of the Medical Library Association 106 (2)]. There are some older studies, although not many, but these suffer because they pre-date extensive changes that have taken place in indexing and electronic citation databases in recent years, including creation and suspension of a number of databases, likely changes in search algorithms - which remain proprietary and cannot be assessed anyway, in addition to the lack of objective measures that might reveal what constitutes a useful bias-free search. The extent of coverage remains ethereal and capricious and if the extant literature comparing various databases is any indication, poorly explored. One may suggest alternative databases to search under the hope for more complete results and less “bias” but all of the terms – bias, completeness, and numerous other proposed comparative terms - remain poorly defined and poorly definable in the present context. There are no objective measures comparing databases so that one can claim bias or lack of bias while notions of either remain unfalsifiable à la Karl Popper’s descriptions.

One recent citation of direct relevance to the present review compared Web of Science, Scopus, and Dimensions and concluded “Dimensions database has the most exhaustive journal coverage, with 82.22% more journals than Web of Science and 48.17% more journals than Scopus [Singh, et al. (2021) Scientometrics 126: 5113-5142]. Although the measurement used was total size of databases by number of journals covered, it illustrates the lack of insightful measures and the difficulties of comparing these and any other databases. The immediate relevance of the publication lies with the use of Dimensions as one of the databases mentioned in the manuscript, albeit a measurement of unverifiable reliability. If the number of studies and number of MICs compiled for microbial strains isolated over the broad range of dates is insufficient to support the conclusions based on the statistical analyses, it defies reason to think that this can be accomplished at all. Of course this is a judgement call ultimately left in the hands of the reviewer, although a population of readers might provide a broader and more complete judgment over time as well as inviting further data gathering and evaluation. Dimensions does cover ClinicalTrials.gov, although it is irrelevant to this manuscript since clinical trials do not report individual MIC values. I think you will find that EMBASE is not considered superior to MEDLINE or PubMed for basic research by many researchers and that the use of EMBASE has not supplanted MEDLINE in systematic reviews (see Kwon, et al. (2014) reference cited above). Science Direct as “not a data base per se” seems irrelevant since it does enable searching other databases, perhaps allowing a broader search than would occur using individual databases.

The original manuscript cited the use of Excel 2013 for statistical analyses, and the point is emphasized more in the revised manuscript. As noted above, the use of meta-regression and other such software is not appropriate for the compiled raw MIC data analyzed here.

Figure 1 has been completed as much as possible. The number of records identified before duplicates are removed was not recorded and is not informative or necessary for any obvious purpose. Why this number is among those in the PRISMA flow diagram is a bit mysterious. The number that matters is what remained after duplicates were removed. Additional records identified through other sources is also a bit ethereal. Does it include only articles used specifically for data or should it include articles included in describing and discussing key points regarding the data? Nevertheless, the number filled into the form is the number of studies found outside the searches and included in data analysis. It isn’t many, since the simple searches resulted in broad selection, including many articles that had one or no MIC values useful for the analyses.

Figures 3 and 22 are provided – now in Supplemental Materials – to address possible questions regarding the use of p-values and heavy and appropriate criticism of their misuse. The use of the term “statistically significant” is assiduously avoided (except in one quoted passage) in keeping with ongoing efforts by statisticians to obliterate use of the term because of its consistent misuse and uninterpretability [for example, see LG Halsey (2019) The reign of the p-value is over: what alternative analyses could we employ to fill the power vacuum? Biology Letters 15: 20190174 and, especially, D Calquhoun (2017) The reproducibility of research and the misinterpretation of p-values. Royal Society Open Science 4(12); 171085]. These are merely a couple of suggestions for relevant reading among what are now hundreds of similar published discussions of how statistics has been misused and has led to a plague of what are described as irreproducible results. Instead it is much more acceptable and informative statistically to provide a collection of p-values based on randomizations, which is what these figures illustrate. Such figures may currently be of little use to non-statisticians, but the literature is increasingly clarifying the issues and solutions that need to be and are gradually and grudgingly being applied in the larger scientific community. I retained the figures albeit in Supplementary Materials but in both the original and revised manuscripts suppressed showing such results for all organisms. Some would say that the omission is an error.

Many details have been moved to Supplementary Materials for each organism and it does read better with the brevity.

The data values in linear regression curves are presented in both manuscript versions with CHX concentration on the ordinate as log2(MIC) values and time on the abscissa. This hasn’t changed and additional coloring based on delivery format (there isn’t any, these are in vitro measurements of CHX MICs) or source would add confusion with no additional clarity. Besides, the necessary explanation of coloring would take paragraphs added to what is already criticized for excessive length.

The “I’m sorry but” fragment is not a sentence and I am left with guessing what the question is. Apparently, the use of non-linear least squares regression analysis to calculate parameters of species subpopulations based on CHX susceptibility was not clear in the original manuscript. The revisions were designed to clarify the meaning. Figures in the main text have been reduced to nine with the intent to emphasize properties of time course and subpopulations for the first three organisms, those with the greatest change in CHX susceptibility over time, and the last three figures to present examples of the types of alternative responses noted in three of the other five species analyzed.

The Discussion has been shortened and its focus sharpened.

Responses to Reviewer #2:

Thank you for your time and efforts in reviewing the long and complicated manuscript.

Please note that the manuscript does not describe a meta-analysis. The distinction between meta-analysis and what is presented here is critical. The report is a compilation of essentially raw values from in vitro measurements of CHX treatment of eight infectious microorganisms. The distinction is more clearly pointed out in the revised manuscript. I extensively reviewed the difference between meta-analysis and a compilation of raw data values for the other reviewer and I will condense the arguments below.

Meta-analysis relies on compiling summary measures of clinical observations, usually in the form of a risk-ratio, logistic model, incidence rate, or analysis requiring multivariate analysis. That is, a single study has a single or small collection of summary values each compiled from raw observations. Meta-analysis compiles the compiled measures/statistics into a new “synthesis” expected to summarize information across the individual studies. This is not the same as a compilation of individual values reported in various studies, which in this manuscript comprise individual values from a variety of studies all using a common and highly standardized laboratory measurement, the MIC. The distinction is essential to understanding, analyzing and interpreting what is contained in the manuscript. The revised manuscript emphasizes the distinction in several places with different contexts (e.g. lines 88-91, 204-213, 221-226).

The main text has been shortened with many figures and tables moved to Supplemental Materials. The relationship between methods and analysis should be clear due to the many revisions in the Methods and Results sections. The relationship between searches and isolation dates has been clarified in numerous places in both sections. The searches covered results from more than the dates of the searches. That is, search results were compiled from searches that covered dates well outside of the search dates. See lines 123-132 (revised manuscript). The only filter used was to compile results using the search algorithm stated in lines 134 – 137 (revised manuscript) regardless of the date of the searches thereby covering publication dates as early as the 1940s. The earliest dates were predominantly from reference strains many of which were isolated in the 1940s and one study used strains from the Murray Collection (reference 35) including many strains isolated in the pre-antibiotic era.

As should be clearer in the revisions, the same pattern of statistical analysis was carried out for all organisms. The pattern is use of linear regression to establish time dependence for susceptibility of strains from various isolation dates, non-linear least squares analysis to assess the presence or absence of subpopulations within the collection of strains assessed for each organism, and examination of strains declared by authors as antibiotic resistant for any relationship between that resistance and resistance to CHX. It is unclear what the comment regarding possible bias introduced by statistical analysis means. In any event, the revised manuscript should be much clearer regarding the consistent patterns of statistical analysis applied.

Original manuscript lines 197 – 203: The number of permutation runs were not always identical, although generally 50 permutation runs were used for linear regression and 10 permutation runs for non-linear least squares regression analysis. In a few cases increased numbers of permutation runs were carried out for particularly important organisms (Pseudomonas aeruginosa) and for organisms that had less precise original data (Klebsiella pneumoniae). The primary measure of fidelity for the values resulting from analyses is the limited SEM associated with parameters regardless of number of permutation runs. This “error determination” is provided in the parameter tables found predominantly in the Supplemental Materials. To explain this in detail would add significant verbiage to the report for limited expected return in clarity in a manuscript being criticized for its length. It seems reasonable to expect that someone questioning the precision of the parameters will be able to find the details in the tables provided.

The relationship between CHX and colistin appears because this is an idea put forth in the literature cited in the Discussion. There is significant concern that resistance to colistin is resulting from the high volume use of CHX (see references 33-35 and many not cited here). More general questions about antibiotic resistance and CHX use have been raised for more years than questions about colistin (see references 26 - 35 and many not cited here). The importance of colistin as an antibiotic of last resort is explicitly stated in lines 599-600. A review that did not include some discussion of the topics would be incomplete. Similarly, failure to discuss ideas indicating mechanisms of resistance to CHX would be incomplete, especially since small changes in resistance to CHX need to be considered in the context of altering metabolic genes which may precede greater resistance as has been observed with clinically important conventional antibiotics (reference 50 and other recent publications not cited here).

Original lines 228-246 have been condensed and modified to conform to guidelines for meta-analysis in response to the other reviewer’s comments, despite the subject not fully conforming to the meta-analysis format.

The goal in all figures was to use uniform symbols with minor exceptions, since the object of the exercises was to compare CHX susceptibility for a wide variety of strains isolated over many years. Part of the message is that the compiled strains are not readily distinguished, since they result from near-identical methodology, i.e. MIC determinations in a liquid dilution format. The goal was also to convey the idea of data densities, which common symbols can accomplish without excess verbiage. The number of figures and the description of results has been abbreviated with the hope that the reader will not get buried in the detail.

Lines 252 – 266 in the original manuscript was eliminated in the revised version and the explanation applicable to line 264 appears in the comments above. Also, the reasons for discussion of colistin is included above.

Although the abbreviation for Pseudomonas aeruginosa as Ps. aeruginosa is not as common as it once was, there are thousands of examples found using Google Scholar, including more than 100 examples in publications as of May 2021. It may originate from investigators who wanted to clearly distinguish between other Gram-negative organisms, e.g. Proteus, although that is pure speculation. Nevertheless, it is unlikely to lead to confusion.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Amal Al-Bakri

5 Aug 2021

Has resistance to chlorhexidine increased among clinically-relevant bacteria? A systematic review of time-course and subpopulation data

PONE-D-20-37954R1

Dear Dr. Buxser, 

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Amal Al-Bakri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Dear Dr. Buxser,

I want to commend you on addressing all commentaries.

To summarize:

1. As a researcher, you have identified a gap in current knowledge that requires definitive verification of whether disinfectant resistance and antibiotic resistance are linked.

2. Well-linked discussion by recalling data found in results, bolstering points being delivered in discussion sections.

3. Results are presented to allow readers to follow the flow of thought patterns and allow eventual conclusions drawn from differences in data.

4. Discussion is well written, no repetition of literature found, and literature complements statements made.

Additional:

1. - line 542 to 545 is a repeat of line 535 to 537.

2. line 590, look into the following statement. I would expect that qacA/B carrying strains would be less susceptible than non qacA/B carrying strains.

"Strains carrying qacA/B had in vitro susceptibility to CHX 3-fold greater than non-qacA/B-carrying strains, but infections caused by the MRSA strains were equally suppressed using a sanitation protocol at typical CHX concentrations "

3. Line 691, I just feel this could be more subtly put, instead of “dead” just passed. (My condolences).

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Acceptance letter

Amal Al-Bakri

11 Aug 2021

PONE-D-20-37954R1

Has Resistance to chlorhexidine increased among clinically-relevant bacteria?  A systematic review of time course and subpopulation data

Dear Dr. Buxser:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Amal Al-Bakri

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA 2009 checklist.

    (DOC)

    S1 Appendix. Statistics for analysis of minimum inhibitory concentration (MIC) data.

    (DOCX)

    S2 Appendix. Detailed species information.

    S1 Table. Linear regression parameters, Ps. aeruginosa, all data. S1 Fig. Distribution of p-values (F-statistic) for slope parameters, Ps. aeruginosa all data. S2 Table. Log-normal parameters for Ps. aeruginosa, all dates. S3 Table. Log-normal parameters for Ps. aeruginosa, pre-1990. S4 Table. Log-normal parameters for Ps. aeruginosa, post-1990. S2 Fig. Fit of log-normal models to Ps. aeruginosa data, post-1990. S5 Table. Linear regression parameters, K. pneumoniae, all dates. S6 Table. Log-normal parameters for K. pneumoniae, all dates. S3 Fig. Fit of log-normal models to K. pneumoniae, antibiotic resistant strains. S7 Table. Log-normal parameters for K. pneumoniae, antibiotic resistant strains. S8 Table. Linear regression parameters, A. baumannii, all dates. S9 Table. Log-normal parameters for A. baumannii, all dates. S4 Fig. Time-course of log2(MIC) values for A. baumannii strains isolated from 2010–2017. S10 Table. Linear regression parameters, A. baumannii, 2010 to 2017. S11 Table. Log-normal parameters for A. baumannii strains isolated after 2010. S5 Fig. Fit of log-normal models to A. baumannii strains isolated after 2010. S12 Table. Log-normal parameters for A. baumannii multi-drug resistant strains isolated after 2010. S13 Table. Linear regression parameters, E. coli, all dates. S6 Fig. Fit of log-normal model to E. coli, all dates. S14 Table. Log-normal parameters for E. coli, all dates. S15 Table. Analysis of antibiotic-resistant E. coli strains. S7 Fig. Time-course of log2(MIC) values for E. faecalis strains, all dates. S16 Table. Linear regression parameters, E. faecalis, all dates. S17 Table. Log-normal parameters for E. faecalis, all dates. S8 Fig. Fit of log-normal model to E. faecalis, all dates. S9 Fig. Time-course of log2(MIC) values for S. epidermidis strains, all dates. S18 Table. Linear regression parameters, S. epidermidis, all dates. S10 Fig. Fit of log-normal model to S. epidermidis, all dates. S19 Table. Log-normal parameters for S. epidermidis, all dates. S20 Table. Linear regression parameters, S. aureus, MSSA. S21 Table. Linear regression parameters, S. aureus, MRSA. S22 Table. Log-normal parameters for S. aureus, MRSA. S23 Table. Log-normal parameters for S. aureus, MSSA. S11 Fig. Distribution of p-values (t-test) S. aureus MRSA vs MSSA. S24 Table. Linear regression parameters, C. albicans, all dates. S12 Fig. Time-course of log2(MIC) values for C. albicans strains, all dates. S13 Fig. Fit of log-normal models to C. albicans, all dates. S25 Table. Log-normal parameters for C. albicans, all dates.

    (DOCX)

    S3 Appendix. Raw data sources.

    (XLSX)

    Attachment

    Submitted filename: Review.pdf

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES